VOLUME 25 1986

SUBJECT INDEX

Abrupt refeeding, 623
  food deprivation
  phentermine
  self-administration
Acarbose, 491
  dietary starch
  intestinal distention
Acetylcholine release, 943
  drug interactions
  locomotor activity
  N-methyl aspartate
Acoustic startle, 1175
  amphetamine
  cocaine
  cross-tolerance
  habituation
  phencyclidine (PCP)
  sensitization
  tolerance
Acute administration
  aggression, 1195
  antipsychotic drugs, 897
  chronic administration, 897, 1195
  magnesium, 1195
  spontaneous chewing movements, 897
  tardive dyskinesia, 897
  tolerance, 1195
Acylating phencyclidines, 51
  calcium antagonist binding
  drug interactions
Adenosine receptors, 769
  hypothermia
  inbred strains
  locomotor activity
  methylxanthines
  theobromine
Adenylate cyclase, 223
  ^{3}H-cyclic AMP
  norepinephrine (NE)
  REM sleep deprivation
Adipsia, 17
  amphetamine
  anorexia
  dopamine terminal area
Adjunctive consumption
  alcohol, 1159, 1163
  drinking, 1159, 1163
  extinction, 1159, 1163
  lithium, 1159, 1163
  shock, 1163
  stress, 1163
  water, 1159
Adrenal cortex, 753
  adrenocorticotrophin 1–24 (ACTH 1–24)
  corticosterone synthesis
  steroidogenesis
alpha$_2$-Adrenergic antagonists, 155
  amphetamine
  in vivo
  locomotor activity
  stereotypy
Adrenergic receptors
  clonidine, 989
  continuous infusion, 989
  dopamine receptors, 763
  drug interactions, 989
  marijuana, 763
  naloxone, 989
  opiate abstinence syndrome, 989
  perinatal exposure, 763
  tyrosine hydroxylase activity, 763
Adrenoceptors, 329
  antidepressants
  ^{3}H-dihydroalprenolol binding
  ^{3}H-prazosin
  REM sleep deprivation
alpha Adrenoceptors, 903
  cerebral cortex
  cold exposure
α_1-Adrenoceptors, 743
  β-adrenoceptors
  functional sensitivity
  noradrenergic denervation
  N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)
β-Adrenoceptors, 743
  α_1-adrenoceptors
  functional sensitivity
  noradrenergic denervation
  N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)
Adrenocorticotrophin 1–24 (ACTH 1–24), 753
  adrenal cortex
  corticosterone synthesis
  steroidogenesis
Age differences
  antinociception, 599
  avoidance conditioning, 673
  cats, 359
  locomotor activity, 599
  maze learning, 673
  memory, 673
  morphine, 599
  phencyclidine (PCP) metabolites, 359
  scopolamine, 673
  tolerance, 359
Aggression
  acute administration, 1195
  bull breeds, 71
  chronic administration, 1195
  limbic system, 71
  magnesium, 1195
  neurotransmitter amino acids, 71
  tolerance, 1195
Alcohol
  adjunctive consumption, 1159, 1163
  drinking, 1159, 1163
  extinction, 1159, 1163
  lithium, 1159, 1163
  shock, 1163
  stress, 1163
  water, 1159
Alcohol dehydrogenase, 1013
  alcohol elimination rate
  alcohol-preferring rats
  free-choice drinking
  metabolic tolerance
Alcohol elimination rate, 1013
  alcohol dehydrogenase
  alcohol-preferring rats
  free-choice drinking
  metabolic tolerance
Alcohol-preferring rats, 1013
  alcohol dehydrogenase
  alcohol elimination rate
  free-choice drinking
  metabolic tolerance
Alternation, 29
  amphetamine
  locomotor excitation
  perseveration
Ambient temperature, 667
  chronic administration
  ethanol
  hypothermia, ethanol-induced tolerance
Amnesia
  anisomycin, 567
  cycloheximide, 567
  drug interactions, 567, 925
  hemicholinium-3, 925
  naloxone, 567
  passive avoidance, 567
  piracetam-like compounds, 925
  shuttle avoidance, 567
Amphetamine
  acoustic startle, 1175
  adipsia, 17
  alpha$_2$-adrenergic antagonists, 155
  alternation, 29
  anorexia, 17
  anorexia, drug induced, 711
  cocaine, 1175
  cross-tolerance, 1175
  dopamine depletion, 1307
  dopamine terminal area, 17
  eating, 1149
  eating motivation, 123
  fenfluramine, 123
  habituation, 1175
  hyperactivity, drug induced, 711
  in vivo, 155
  lesions, 6-hydroxydopamine (6-OHDA), 1307
  lesions, substantia nigra, 1307
  locomotor activity, 115, 161, 1149
  locomotor excitation, 29
  metabolic rate, 161
  naloxone, 123
  naltrexone, 123
  nucleus accumbens, 1149
  perseveration, 29
  phencyclidine (PCP), 1175
  phenylethylamine (PEA), 711

recovery, 1307
rotation, 1307
satiety, 123
sensitization, 1175
stereotypy, 155
tolerance, 1175
Amphetamine-induced hyperactivity, 919
estrogen
time-dependent modulation
Amphetamine self-administration
brain catecholamines, 1027
L-tryptophan, 849
L-tyrosine, 1027
d-Amphetamine
bin analysis, 145
inter-response time, 145
monkeys, 145
Sidman avoidance schedule, 145
simultaneous brightness discrimination, 939
two stage administration, 939
Analgesia
benzodiazepine receptors, 215
classical conditioning, 1201
environmental specific cues, 1201
habituation, 1201
morphine, 215, 1201
snails, 1201
stress, 1201
tolerance, 1201
Analgesia, stress-induced, 171
cold water swim
hyperphagia
hypothermia
muscarinic agents
pain
Analgesiometry, 481
ear-withdrawal
rabbits
Anesthesia, 641
antinociception
cardiovascular system
[D-Ala^2]-methionine enkephalinamide (DALA)
renal sympathetic nerve
Angiotensin converting enzyme (ACE) activity, 953
aspartic acid
brain asparaginase
morphine dependent rats
naloxone
plasma cortisol level
Anhedonia
duration of response, 615
force of response, 615
haloperidol, 1231
licking, 219
partial reinforcement extinction effect, 1231
pimozide, 219, 615
response rate, 615
reward omission, periodic, 1231
sucrose concentration, 219
water reinforcement, 1231
Animal model, 297
Huntington's disease
locomotor hyperactivity
neural transplants
Anisomycin, 567
amnesia
cycloheximide
drug interactions
naloxone
passive avoidance
shuttle avoidance
Anorexia
adipsia, 17
amphetamine, 17
dopamine terminal area, 17
eating, 99
fenfluramine, 967
FG 7142, 99
gastrointestinal tract, 967
grooming, 99
hyperphagia, 99
locomotor activity, 99
midazolam, 99
opioid peptides, 967
Anorexia, drug induced, 711
amphetamine
hyperactivity, drug induced
phenylethylamine (PEA)
Anticonvulsant effects, 1059
bicuculline
drug interactions
$GABA_A$ receptors
maximal electroshock
pentobarbital
phenobarbital
picrotoxin
seizures
Antidepressants
adrenoceptors, 329
^{3}H-dihydroalprenolol, 329
escape deficit, 1
inescapable shock, 1
intraspecies behavior, 515
learned helplessness, 1
locomotor activity, 515
model of depression, 805
pharmaco-ethological analysis, 515
^{3}H-prazosin, 329
REM sleep deprivation, 329
serotonergic neurons, 1
serotonergic receptors, 805
Antinociception
age differences, 599
anesthesia, 641
cardiovascular system, 641
drug comparisons, 835
drug interactions, 835
locomotor activity, 599
[D-Ala^2]-methionine enkephalinamide (DALA), 641
morphine, 599, 835
renal sympathetic nerve, 641
tizanidine, 835
tolerance, 835
Antinociceptive system, 533
morphine
opiate tolerance
stimulation-produced analgesia
Antipsychotic drugs, 897
acute administration
chronic administration
spontaneous chewing movements
tardive dyskinesia
Anxiety
anxiolytic drugs, 371
beta-blockers, 371
convulsions, 595
6,7-dimethoxy, 4 ethyl β-carboline carboxylic acid methyl ester, 595
locomotor activity, 595
naltrexone, 595
pigeons, 371
propunishment, 595
punished responding, 371
Anxiolytic drugs, 371
anxiety
beta-blockers
pigeons
punished responding
Apomorphine
behavioral deficits, 503
cognitive deficits, 503
dopamine receptors, 473
dopaminergic mechanism, 693
exploratory behavior, 473
lateralized rotation, 689
neuroleptics, 473, 503
operant behavior, 503
postural asymmetry, 689
shock escape mechanisms, 693
Apormorphine-induced stereotypy, 757
dopaminergic neuron activity
MSH-release inhibiting factor-1 (MIF-1)
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
Apparatus
Animex activity meter, 411
8-choice arena, 747
holeboard, 473
intracerebral cannula system, 487
osmotic minipump, 1263
radial arm maze, 521, 703, 747, 1117
radiant heat apparatus, 481
rotometer, 1021
runway, 123
shuttlebox, 145
toggle-box, 289
Y catheter, 483
Y-maze, 29, 939
Appetite regulation, 381
deprivation
eating
glucoprivic feeding
lesions, paraventricular nucleus (PVN)
Appetite suppressants, 733
brown adipose tissue (BAT)
purine nucleotide binding
Appetitive learning, 651
brain DNA
DNA synthesis
reverse handedness
Area postrema, 269
conditioned taste aversion
locomotor activity
scopolamine
N-methyl Aspartate, 943
acetylcholine release
drug interactions
locomotor activity
Aspartic acid, 953
angiotensin converting enzyme (ACE) activity
brain asparaginase
morphine dependent rats
naloxone
plasma cortisol level
Ca^{++}-ATPase activity, 549
dihydropyridine receptors
thermoregulation
Atropine, 985
clonidine

drug interactions
locomotor activity
stereotypy
Autoradiography, 1051
discriminative stimulus properties
^{3}H-PCP binding potency
phencyclidine (PCP)-related compounds
Avoidance conditioning, 673
age differences
maze learning
memory
scopolamine
Avoidance learning, 469
inhibitory avoidance
substance P

Barrel rotation
behavioral changes, 589
lesions, kainic acid, 583, 589
nicotine, 583
prostration, 583
receptors changes, 589
vasopressin, 583
vestibular cerebellum, 583
Bat/rat/mouse/hamster comparisons, 527
brain opioid receptors
hibernation
Behavioral analysis, 577
caloric intake
eating
human studies, males
marijuana
Behavioral changes, 589
barrel rotation
lesions, kainic acid
receptor changes
Behavioral deficits, 503
apomorphine
cognitive deficits
neuroleptics
operant behavior
Behavioral despair test, 511
H_2-receptor blockers
naloxone
Behavioral development, 1089
lead retention
preweaning lead exposure
Benzodiazepine antagonists, 537
drug interactions
schedule-controlled behavior
Benzodiazepine receptors, 215
analgesia
morphine
Benzodiazepines
brown adipose tissue (BAT), 913
cafeteria diet, 913
chickens, 1237
chlordiazepoxide, 1237
conditioned taste aversion, 431
convulsions, 1145
drinking, 431
food intake, 913
food preference, 913
hyperactivity, 1145
neonates, 1145
polydipsia, 431
tolerance, 1237
tonic immobility, 1237
two-bottle choice paradigm, 431
type 2 receptors, 1145
Beta-blockers, 371
anxiety
anxiolytic drugs
pigeons
punished responding
Bicuculline, 1059
anticonvulsant effects
drug interactions
$GABA_A$ receptors
maximal electroshock
pentobarbital
phenobarbital
picrotoxin
seizures
Bin analysis, 145
d-amphetamine
inter-response time
monkeys
Sidman avoidance schedule
Blood pressure, 423
chemical stimulation
heart rate
mediodorsal nucleus of the thalamus
rabbits
Body temperature, 1293
diisopropylfluorophosphate (DFP)
heart rate
locomotor activity
muscarinic receptors
^{3}H-quinuclidinyl benzilate (^{3}H-QNB) binding
respiration rate
tolerance
Body weight, 1131
caloric intake
nicotine
physical activity
rats, females
Bombesin, 7
cholecystokinin (CCK)
dietary self-selection
isocaloric diets
Brain
amygdala, 17, 95
anterior hypothalamus, 353
anteromedial caudate nucleus, 17
basal ganglia, 233
brainstem, 1253
caudal medulla, 347
caudate nucleus, 63, 521
cerebellum, 555
cerebral cortex, 1, 527, 743, 763, 903
cochlear nucleus, 347, 353
corpus striatum, 943
cortex, 329, 521, 555, 1293
dorsal hippocampus, 717
dorsal raphe nucleus, 717, 1211
entorhinal cortex, 651
fourth ventricle, 843
globus pallidus, 233
hippocampus, 1, 347, 423, 521, 651, 743, 781, 797, 1137, 1293
hypothalamus, 95, 381, 411, 527, 549, 555
lateral habenula nuclei, 717
lateral hypothalamus (LH), 59, 629
lateral ventricle, 411
locus coeruleus, 1211
magnocellular basal forebrain, 293
medial forebrain bundle, 629
medial frontal cortex, 17
medial hypothalamus, 401, 1223
medial prefrontal cortex, 191
medial septum, 521
median raphe nucleus, 717, 1211
midbrain central grey, 857
midbrain raphe, 1
midmesencephalon, 347
nodular cerebellum, 583, 589
nucleus accumbens, 17, 63, 263, 943, 1095, 1149
nucleus accumbens septi, 1027
nucleus basalis magnocellularis, 521
olfactory tubercule, 63
paramedian brainstem, 347
paraventricular nucleus (PVN), 381, 1223
pituitary, 967
pontine reticular formation (PRF), 1253
prefrontal cortex, 717
preoptic region, 353
right frontoparietal cortex, 263
septum, 95, 797
somatosensory cortex, 607
striatum, 1, 297, 763, 865, 1027, 1095, 1293
substantia nigra, 317, 1307
thalamus, 423
ventral striatum, 233
ventral tegmental area, 959
ventrolateral caudate nucleus, 17
ventromedial hypothalamus (VMH), 59
vestibular cerebellum, 583
visual cortex, 651
Brain asparaginase, 953
angiotensin converting enzyme (ACE) activity
aspartic acid
morphine dependent rats
naloxone
plasma cortisol level
Brain catecholamines, 1027
amphetamine self-administration
L-tyrosine
Brain DNA, 651
appetitive learning
DNA synthesis
reverse handedness
Brain iron-deficiency, 141
learning
water maze
Brain monoamines, 401
hyperphagia
lesions, medial hypothalamus
obesity
Brain noradrenergic system, 411
l-erythro-dihydroxyphenylserine (L-erythro-DOPS)
locomotor activity
Brain opioid receptors, 527
bat/rat/mouse/hamster comparisons
hibernation
Brain stimulation, 629
drug interactions
nalbuphine
reward threshold
tripilennamine
Brown adipose tissue (BAT)
appetite suppressants, 733
benzodiazepines, 913
cafeteria diet, 913
food intake, 913
food preference, 913
purine nucleotide binding, 733

Buccal mucosa, 1181
human studies
nicotine absorption
passive smoking
Bull breeds, 71
aggression
limbic system
neurotransmitter amino acids
Buspirone, 457
corticosterone secretion
prolaction secretion
stress
BW813U, 521
choline acetyltransferase (ChAT) inhibitor
radial maze performance
spatial memory

Cafeteria diet, 913
benzodiazepines
brown adipose tissue (BAT)
food intake
food preference
Caffeine, 1271
locomotor activity
strain differences
theophylline
Calcium antagonist binding, 51
acylating phencyclidines
drug interactions
Calcium antagonists, 45
drug interactions
motor activity
phencyclidine (PCP)
Calcium channel antagonists, 555
drug interactions
hyperthermia
thermoregulation
Caloric intake
behavioral analysis, 577
body weight, 1131
eating, 577
human studies, males, 577
marijuana, 577
nicotine, 1131
physical activity, 1131
rats, females, 1131
Cannabidiol, 89
cats
electrophysiological properties
spinal motoneurons
synaptic effects
Carbon monoxide exposure, 1245
filter vent blocking
human studies
smoking topography
tobacco
Cardiovascular system, 641
anesthesia
antinociception
[D-Ala²]-methionine enkephalinamide
renal sympathetic nerve
Cataleptic behavior, 463
drug interactions
neuroleptics
prostaglandins
Catecholamines, 949
α-methyl-p-tyrosine
6-hydroxydopamine (6-OHDA)
seizures, pentylenetetrazol (PTZ) induced

l-Cathinone
chronic administration, 13
dopaminergic neuronal systems, 337
drug discrimination, 13, 337
drug interactions, 337
tolerance, 13
Cats
age differences, 359
cannabidiol, 89
electrophysiological properties, 89
phencyclidine (PCP) metabolites, 359
spinal motoneurons, 89
synaptic effects, 89
tolerance, 359
Cerebral cortex, 903
alpha adrenoceptors
cold exposure
CGS 8216
drinking, 341
drug interactions, 439
ethanol, 439
naltrexone, 439
saccharin consumption, 341
shock avoidance, 439
timeout from avoidance, 439
Chemical stimulation, 423
blood pressure
heart rate
mediodorsal nucleus of the thalamus
Chickens, 1237
benzodiazepines
chlordiazepoxide
tolerance
tonic immobility
Chicks, 823
memory
testosterone
Chlordiazepoxide
benzodiazepines, 1237
chickens, 1237
sodium valproate, 747
spatial behavior, 747
tolerance, 1237
tonic immobility, 1237
Chlordiazepoxide-induced sleep, 1077
GABAergic drugs
selective breeding
N-(2-Chloroethyl-N-ethyl-2-bromobenzylamine (DSP-4), 743
α_1-adrenoceptors
β-adrenoceptors
functional sensitivity
noradrenergic denervation
Cholecystokinin (CCK)
bombesin, 7
dietary self-selection, 7
hamsters, 1067
hyperactivity, 1067
hypoactivity, 1067
isocaloric diets, 7
morphine, 1067
Cholesterol, 1285
dietary manipulation
essential fatty acids
ethanol preference
hamsters
retinal palmitate
Choline acetyltransferase (ChAT) inhibitor, 521
BW813U
radial maze performance
spatial memory

Cholinesterase inhibition, 1071
clinical chemistry
heat
pyridostigmine
thermoregulation
Cholinesterase inhibitors, 1217
perioral behaviors
physostigmine
tardive dyskinesia
Cholinomimetics, 1253
chronic microinfusion
rapid eye movement (REM) sleep
Chronic administration
acute administration, 897, 1195
aggression, 1195
ambient temperature, 667
antipsychotic drugs, 897, 1195
l-cathinone, 13
dopamine receptors, 129
drug discrimination, 13
ethanol, 667
hypothermia, ethanol-induced, 667
magnesium, 1195
motor activity, 129
phenylethylamine, 129
sensitization, 129
spontaneous chewing movements, 897
tardive dyskinesia, 897
tolerance, 13, 667, 1195
Chronic infusion, 483
intrathecal injection
tolerance
Chronic microinfusion, 1253
cholinomimetics
rapid eye movement (REM) sleep
Circadian rhythm, 333
sedation hypnosis
sleep time
strain differences
Circling behavior, 1021
locomotor activity
prenatal alcohol exposure
Circling, opiate-induced, 959
dopaminergic system
opiate receptors
ventral tegmental area
Classical conditioning
analgesia, 1201
cross tolerance, 35
drug reinforcement, 1169
environmental specific cues, 1201
ethanol, 35
exploratory behavior, 1169
habituation, 1169, 1201
morphine, 1169, 1201
place preference, 1169
snails, 1201
sodium pentobarbital, 35
stress, 1201
stress-induced analgesia, 181
tail flick, 181
tolerance, 1201
Clinical chemistry, 1071
cholinesterase inhibition
heat
pyridostigmine
thermoregulation
Clonidine
adrenergic receptors, 989
atropine, 985
continuous infusion, 989
drug interactions, 985, 989

eating, 1107
hamsters, 1107
locomotor activity, 985
naloxone, 989
opiate abstinence syndrome, 989
stereotypy, 985
Cocaine
acoustic startle, 1175
amphetamine, 1175
cross-tolerance, 1175
habituation, 1175
haloperidol, 497
lesions, neurotoxic, 191
medial prefrontal cortex, 191
phencyclidine (PCP), 1175
presynaptic dopaminergic terminal, 191
self-administration, 497
self-administration, intracranial, 191
sensitization, 1175
sex differences, 497
tamoxifen, 497
tolerance, 1175
Cochlear nucleus (CN), 353
prostaglandin (PGE_1)
pyrexia
Cognitive deficits, 503
apomorphine
behavioral deficits
neuroleptics
operant behavior
Cold exposure, 903
alpha adrenoceptors
cerebral cortex
Cold-restraint stress, 775
gastric ulceration
motility
Cold water swim, 171
analgesia, stress-induced
hyperphagia
hypothermia
muscarinic agents
pain
Conditioned aversions, 973
drug-paired stimuli
lever pressing
lithium chloride (LiCl)
monkeys
Conditioned hyperactivity hypothesis, 83
drug interactions
thermic response shifts
Conditioned place aversion, 1041
conditioned place preference
locomotor activity
nicotine
Conditioned place preference
conditioned place aversion, 1041
drug reinforcement, 1101
locomotor activity, 1041
morphine, 1101
nicotine, 1041
single-trial, 1101
Conditioned taste aversion
area postrema, 269
benzodiazepines, 431
drinking, 431
duration of action, 995
locomotor activity, 269
polydipsia, 431
scopolamine, 269
temporal analysis, 995
tryptamine, 995
two-bottle choice paradigm, 431
Consolidation, 1125
memory effects, time related
passive avoidance behavior
retrieval
vasopressin
vasopressin analogues
Continuous infusion, 989
adrenergic receptors
clonidine
drug interactions
naloxone
opiate abstinence syndrome
Convulsions
anxiety, 595
benzodiazepines, 1145
6,7-dimethy, 4 ethyl β-carboline carboxylic acid methyl ester, 595
hyperactivity, 1145
locomotor activity, 595
naltrexone, 595
neonates, 1145
propunishment, 595
type 2 receptors, 1145
Corticosterone, 107
oxytocin
psychological stressor
Corticosterone secretion, 457
buspirone
prolactin secretion
stress
Corticosterone synthesis, 753
adrenal cortex
adrenocorticotrophin 1–24 (ACTH 1–24)
steroidogenesis
Cross tolerance
acoustic startle, 1175
amphetamine, 1175
classical conditioning, 35
cocaine, 1175
ethanol, 35
habituation, 1175
phencyclidine (PCP), 1175
sensitization, 1175
sodium pentobarbital, 35
tolerance, 1175
^{3}H-Cyclic AMP, 223
adenylate cyclase
norepinephrine (NE)
REM sleep deprivation
Cyclo (leucyl-glycyl) (cLG), 1279
dopamine receptors
haloperidol
stereotypy, apomorphine-induced
supersensitivity
Cycloheximide, 567
amnesia
anisomycin
drug interactions
naloxone
passive avoidance
shuttle avoidance
Cytisine, 843
dogs
fourth ventricle
high/low affinity sites
2-methylpiperidine
nicotine

D_2 receptors, 1185
dopamine
internal clock speed
neuroleptics
time estimation
Deer mouse, 543
food hoarding
ingestion
opiate agonists
Defensive behavior, 561
diazepam
environmental constraints
fear reactions
Delayed-matching-to-sample, 929
drug interactions
phenobarbital
phenytoin
pigeons
valproic acid
Delayed performance, 201
monkeys
phencyclidine (PCP)
repeated acquisition
response chains
retention
Delayed response, 633
discrimination
response bias
scopolamine
working memory
2-Deoxy-D-glucose
feeding behavior, 59
glucoprivation, 1153
hyperphagia, 59
hypophagia, 1153
lateral hypothalamus, 59
liquid diet, 1153
5-thioglucose, 59
ventromedial hypothalamus, 59
water deprivation, 1153
Deprivation
appetite regulation, 381
eating, 381, 1223
glucoprivic feeding, 381
lesions, paraventricular nucleus (PVN), 381
medial hypothalamus, 1223
norepinephrine (NE), 1223
paraventricular nucleus (PVN), 1223
serotonin, 1223
Diazepam, 561
defensive behavior
environmental constraints
fear reactions
Dietary manipulation, 1285
cholesterol
essential fatty acids
ethanol preference
hamsters
retinol palmitate
Dietary self-selection, 7
bombesin
cholecystokinin (CCK)
isocaloric diets
Dietary starch, 491
acarbose
intestinal distention
Differential reinforcement of low rate of response (DRL), 1191
fixed ratio performance
operant behavior
3-quinuclidinyl benzilate (QNB)
schedule dependent effects
^{3}H-Dihydroalprenolol binding, 329
adrenoceptors

antidepressants
^{3}H-prazosin
REM sleep deprivation
Dihydropyridine receptors, 549
Ca^{++}-ATPase activity
thermoregulation
Diisopropylfluorophosphate (DFP), 1293
body temperature
heart rate
locomotor activity
muscarinic receptors
^{3}H-quinuclidinyl benzilate (^{3}H-QNB) binding
respiration rate
tolerance
6,7-Dimethy, 4 ethyl β-carboline
carboxylic acid methyl ester (DMCM), 595
anxiety
convulsions
locomotor activity
naltrexone
propunishment
Diphenhydramine, 365
driving related tasks
human studies, males
plasma levels
Discrimination, 633
delayed response
response bias
scopolamine
working memory
Discriminative stimulus properties, 1051
autoradiography
^{3}H-PCP binding potency
phencyclidine (PCP)-related compounds
Diurnal cycle, 293
lesions, nucleus basalis magnocellularis
locomotor activity
DNA synthesis, 651
appetitive learning
brain DNA
reverse handedness
Dogs, 843
cytisine
fourth ventricle
high/low affinity sites
2-methylpiperidine
nicotine
DOPAC concentrations, 63
electrical stimulation
intracranial self-stimulation
in vivo
nigro-striatal pathway
DOPAC/DA ratio, 865
dopamine release
striatal dopamine system
unilateral barpressing
Dopamine, 1185
D_2 receptors
internal clock speed
neuroleptics
time estimation
Dopamine agonists, 249
dopamine antagonists
locomotor activity
Dopamine antagonists, 249
dopamine agonists
locomotor activity
Dopamine autoreceptor agonists, 255
exploratory activity
locomotor activity, drug-induced
Dopamine depletion, 1307
amphetamine
lesions, 6-hydroxydopamine (6-OHDA)
lesions, substantia nigra
recovery
rotation
Dopamine metabolism, 1095
feeding behavior
ingestion
nucleus accumbens
striatum
Dopamine receptors
adrenergic receptors, 763
apomorphine, 473
chronic administration, 129
cyclo (leucyl-glycyl) (cLG), 1279
exploratory behavior, 473
haloperidol, 1279
marijuana, 763
motor activity, 129
neuroleptics, 473
perinatal exposure, 763
phenylethylamine (PEA), 129
sensitization, 129
stereotypy, apomorphine-induced, 1279
supersensitivity, 1279
tyrosine hydroxylase activity, 763
Dopamine release, 865
DOPAC/DA ratio
striatal dopamine system
unilateral barpressing
Dopamine systems, 1117
LY 171555
radial arm maze
Dopamine terminal area, 17
adipsia
amphetamine
anorexia
Dopaminergic mechanisms, 693
apomorphine
shock escape learning
Dopaminergic neuron activity, 757
apomorphine-induced stereotypy
MSH-release inhibiting factor-1 (MIF-1)
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
Dopaminergic neuronal systems, 337
l-cathinone
drug discrimination
drug interactions
Dopaminergic system, 959
circling, opiate-induced
opiate receptors
ventral tegmental area
Dose-dependent effects, 1207
drug discrimination
5-methoxy-N,N-dimethyltryptamine (5-OMe DMT)
serotonin antagonists
stimulus properties
Drinking
adjunctive consumption, 1159, 1163
alcohol, 1159, 1163
benzodiazepines, 431
CGS 8216, 341
conditioned taste aversion, 431
extinction, 1159, 1163
hamsters, 449
high-calorie fluids, 449
lithium, 1159, 1163
morphine, 1001
naloxone, 697
naloxone-precipitated withdrawal, 1001
opioid agonists, 77
palatability, 697
physical dependence, 1001
polydipsia, 431
reproduction, 449
saccharin consumption, 341
satiation, 697
sequential presentation, 697
shock, 1163
social stress, 449
stress, 1163
sucrose, 1001
two-bottle choice paradigm, 431
water, 1159
water balance, 77
Driving related tasks, 365
diphenhydramine
human studies, males
plasma levels
Drug
alcohol, 1159, 1163
amino-oxyacetic acid, 1077
aminophosphonovaleric acid, 943
amisulpride, 503
ammonium sulfate, 161
amphetamine, 17, 129, 155, 161, 277, 515, 711, 919, 1149, 1175, 1307
d-amphetamine, 29, 123, 145, 255, 297, 733, 849, 939, 1021, 1027
anisomycin, 567
apomorphine, 41, 255, 277, 473, 503, 689, 757, 1279
apomorphine hydrochloride, 693
artificial cerebrospinal fluid (5-ion), 411
l-aspartic acid, 953
aspirin, 463
atenolol, 371
atropine, 775, 897, 985
atropine sulfate, 83
baclofen, 1059
BAY K8644, 549, 555
bethanechol, 775
bicuculline, 59, 1059, 1077
brotizolam, 913
buspirone, 457
BW813U, 521
caffeine, 277
cannabidiol, 89
cannabinol monoethyl ether, 393
captopril, 317
carbachol, 423, 1253
l-cathinone, 13, 337
CGS 8216, 341, 439, 537
chlordiazepoxide, 43 , 747, 973, 1077, 1237
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), 743
p-chlorophenylalanine (PCPA), 415
chlorpromazine, 255, 503, 805, 897, 1185
choline, 925
cimetidine, 511
cinanserin, 1207, 1223
cis-flupenthixol, 473
CL 218,872, 1145
clomipramine, 1, 515, 805
clonazepam, 1145

clonidine, 835, 985, 989, 1107, 1211
clozapine, 255, 897
cocaine, 191, 497, 1175
cycloheximide, 567
N^6cyclohexyladenosine, 1271
cyproheptadine, 1207
cytisine, 843
2-deoxy-D-galactose, 1137
2-deoxy-D-glucose, 59, 171, 1153
desipramine, 1, 805
dexamethasone, 781
dextrorphan tartrate, 959
diazepam, 215, 431, 537, 561, 913, 1145
N-N-diethylaminephenylhexylamine, 359
diethylpropion, 733
dihydropyridine, 51
5,7-dihydroxytryptamine, 1
diisopropylfluorophosphate (DFP), 1293
diltiazem, 51, 549, 555
6,7-dimethoxy, 4 ethyl β-carboline carboxylic acid methyl ester (DMCM), 595
1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), 135
4-(5,6)-dimethyl-2-benzofuranyl/piperidine hydrochloride (CGP 6085 A), 743
diprenorphine HCl, 959
dopamine, 191, 813, 943, 1185
doxepine, 805
EMD 23448, 255
L-erythro-dihydroxyphenylserine (L-erythro-DOPS), 411
ethanol, 35, 289, 333, 439, 607, 667, 889, 1013, 1021, 1035, 1083, 1285
5'-(N-ethylcarboxamide) adenosine, 769, 1271
ethylketazocine methanesulfonate, 959
ethylketocyclazocine, 77
etiracetam, 925
fenfluramine, 123, 733, 967, 1223
FG 7142, 99
fluoxetine, 515
fluphenazine, 503, 897
FOURPHIT, 51
l-glutamate, 423
haloperidol, 255, 337, 463, 473, 497, 503, 791, 813, 897, 959, 1175, 1185, 1231, 1279
harmine, 111
hemicholinium-3, 925
hydralazine, 317
p-hydroxyamphetamine, 161
6-hydroxydopamine (6-OHDA), 191, 381, 401, 949
8-hydroxy-2-(di-n-propylamino) tetralin (8-OH DPAT), 135
N-(5-hydroxypentyl)-1-phencyclohexylamine, 359
5-hydroxytryptamine (5-HT), 23, 849, 883
5-hydroxy-L-tryptophan (5-HTP), 805, 873
idazoxan, 903
imipramine, 1, 149, 805
indomethacin, 739
iprazid, 515
kainic acid, 297, 589
ketamine, 111
ketanserin, 135
ketocyclazocine hydrochloride, 543
lead, 1089
levorphanol bitartrate, 959
lithium chloride (LiCl), 431, 973, 1159, 1163
lorazepam, 1145
LY 171555, 1117
lysergic acid diethylamide (LSD), 41, 227, 717
magnesium, 1195
marijuana, 577, 763
mazindol, 733
METAPHIT, 51
metazocine, 785
metergoline, 1223
methadone, 149, 959
d-methamphetamine, 1035
methanesulfonyl fluoride, 1217
methergoline, 1207
[D-Ala^2]-methionine enkephalinamide (DALA), 641
5-methoxy-N,N-dimethyltryptamine (5-OMe DMT), 1207
N-methyl aspartate (NMA), 943
2-methylpiperidine, 843
methylscopolamine, 171, 633, 673
[^{3}H-methyl]thymidine, 651
α-methyl-p-tyrosine (α-MPT), 949
methysergide, 23, 805, 1207, 1223
metoclopramide, 473, 503
mianserin, 805
midazolam, 99
morphine, 77, 209, 215, 481, 533, 555, 599, 835, 1001, 1007, 1067, 1101, 1169, 1201, 1263
morphine sulphate, 959
muscimol, 1059
nalbuphine, 629
naloxone, 123, 209, 511, 533, 543, 567, 697, 835, 953, 989, 1007, 1101, 1263
naloxone hydrochloride, 555, 959
naltrexone, 123, 439, 575, 595, 959
nialamide, 1, 943
nicotine, 185, 277, 583, 589, 727, 843, 879, 1131
nifedipine, 45
nimodipine, 549, 555
nitrendipine, 51
norepinephrine (NE), 223, 381
8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT), 883
oxotremorine, 1293
oxytocin, 107
pentetrazole, 41
pentobarbital, 333, 375, 835, 1059
pentylenetetrazol (PTZ), 949, 1077
phencyclidine (PCP), 45, 51, 117, 129, 185, 201, 359, 785, 827, 1175
phencyclidine hydrochloride, 959
phenobarbital, 929, 1059
phentermine, 623
1-phenylcyclohexylamine, 827
1-(1-phenylcyclohexyl)-4-hydroxypiperidine, 827
(−)N^6phenylisopropyladenosine, 1271
1-(1-phenyl-4-hydroxycyclohexyl) piperidine, 827
phenylephrine, 743
phenylethylamine (PEA), 129, 711
phenylmethanesulfonyl fluoride, 1217
phenytoin, 929
physostigmine, 1217
picrotoxin, 59, 1059, 1077
pilocarpine, 463
pimoline, 933
pimozide, 219, 503, 615, 711, 1185
piperoxan, 155
piracetam, 925
pirenperone, 111
pizotyline, 227
pramiracetam, 925
prazosin, 903
procaine, 583, 857
promazine, 1185
propranolol, 23, 41, 135, 371, 463
N-n-propyl-3-(3-hydroxyphenyl)-piperidine (3-PPP), 255
N-n-propylnorapomorphine (NPA), 255
pyrazidol, 515
pyridostigmine, 1071
3-quinuclidinyl benzilate (QNB), 1191
racemic N-allyl-N-normetazocine (SKF 10,047), 959
ranitidine, 511
rauwolscine, 155
Ro 15-1788, 215, 537, 1145
RS 21361, 155
RX-781094, 155, 903
SCH 23390, 473
scopolamine, 171, 277, 673, 1253
scopolamine hydrochloride, 269
scopolamine methyl nitrate, 269
secobarbital, 375
serotonin, 191, 1223
SKF 83566, 249
sodium pentobarbital, 35, 83
sodium valproate (VPA), 747
spiperone, 135
spiroperidol, 1185
sulpiride, 191, 473, 503, 897
tamoxifen, 497
Δ^1-tetrahydrocannabinol (Δ^1-THC), 393
Δ^8-tetrahydrocannabinol (Δ^8-THC), 827
tetrodotoxin, 857
theobromine, 769
5-thioglucose, 59
thioridazine, 503, 897
tizanidine, 835
tolazoline, 155
trazodone, 515, 805
1-(3-trifluoromethylphenyl)piperazine (TFMPP), 135
tripelennamine, 629
tryptamine, 995
L-tryptophan, 849
L-tyrosine, 1027
U50,488H, 77, 543
valproic acid, 929
verapamil, 45, 227, 549, 555, 775
yohimbine, 155
zimelidine, 805
zolpidem, 537

Drug comparisons
antinociception, 835
drug interactions, 835, 1035
ethanol, 1035
inhibition and stimulation, 1035
locomotor activity, 1035
d-methamphetamine, 1035
morphine, 835

tizanidine, 835
tolerance, 835
Drug discrimination
l-cathinone, 13, 337
chronic administration, 13
dopaminergic neuronal systems, 337
dose-dependent effects, 1207
drug interactions, 337
hexahydrocannabinol stereochemistry, 393
8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH DPAT), 135
ketanserin pretreatment, 135
metazocine, 785
5-methoxy-N,N-dimethyltryptamine (5-OMe DMT), 1207
monkeys, 785
morphine, 209
naloxone antagonism, 209
phencyclidine (PCP), 117
pigeons, 117, 209
plasma phencyclidine, 117
rat/pigeon comparisons, 393
self-administration, 785
serotonin antagonists, 1207
stimulus properties, 785, 1207
tetralin analogues, 135
tolerance, 13
Drug interactions
acetylcholine release, 943
acylating phencyclidines, 51
adrenergic receptors, 989
amnesia, 567, 925
anisomycin, 567
anticonvulsant effects, 1059
antinociception, 835
atropine, 985
benzodiazepine antagonists, 537
bicuculline, 1059
brain stimulation, 629
calcium antagonist binding, 51
calcium antagonists, 45
calcium channel antagonists, 555
cataleptic behavior, 463
l-cathinone, 337
CGS 8216, 439
clonidine, 985, 989
conditioned hyperactivity hypothesis, 83
continuous infusion, 989
cycloheximide, 567
delayed-matching-to-sample, 929
dopaminergic neuronal systems, 337
drug comparisons, 835, 1035
drug discrimination, 337
endogenous opioids, 1007
ethanol, 439, 1035
$GABA_A$ receptors, 1059
hemicholinium-3, 925
5-hydroxytryptamine (5-HT), 23
hyperdipsia, 23
hyperthermia, 555
hypophagia, 23
imipramine, 149
inhibition and stimulation, 1035
locomotor activity, 943, 985, 1035
maximal electroshock, 1059
methadone, 149
d-methamphetamine, 1035
N-methyl aspartate (NMA), 943
methysergide, 23
monkeys, 185
morphine, 835
motor activity, 45
nalbuphine, 629
naloxone, 567, 989
naltrexone, 439
neuroleptics, 463
nicotine, 185
opiate abstinence syndrome, 989
opiates, 1007
passive avoidance, 567
pentobarbital, 1059
phencyclidine (PCP), 45, 185
phenobarbital, 929, 1059
phenytoin, 929
picrotoxin, 1059
pigeons, 149, 929
piracetam-like compounds, 925
postpartum aggression, 1007
propranolol, 23
prostaglandins, 463
repeated acquisition, 185
response chains, 185
reward threshold, 629
schedule-controlled behavior, 537
seizures, 1059
shock avoidance, 439
shuttle avoidance, 567
stereotypy, 985
thermic response shifts, 83
thermoregulation, 555
timeout from avoidance, 439
tizanidine, 835
tolerance, 835
tripelennamine, 629
valproic acid, 929
variable interval schedule, 149
Drug-paired stimuli, 973
conditioned aversions
lever pressing
lithium chloride (LiCl)
monkeys
Drug reinforcement
classical conditioning, 1169
conditioned place preference, 1101
exploratory behavior, 1169
habituation, 1169
morphine, 1101, 1169
place preference, 1169
single-trial, 1101
Duration of action, 995
conditioned taste aversion
temporal analysis
tryptamine
Duration of response, 615
anhedonia
force of response
pimozide
response rate

Ear-withdrawal, 481
analgesiometry
rabbits
Eating
amphetamine, 1149
anorexia, 99
appetite regulation, 381
behavioral analysis, 577
caloric intake, 577
clonidine, 1107
deprivation, 381, 1223
FG 7142, 99
glucoprivic feeding, 381
grooming, 99
hamsters, 1107
human studies, males, 577
hyperphagia, 99
lesions, paraventricular nucleus (PVN), 381
locomotor activity, 99, 1149
marijuana, 577
medial hypothalamus, 1223
midazolam, 99
norepinephrine (NE), 1223
nucleus accumbens, 1149
paraventricular nucleus (PVN), 1223
rearing, 99
serotonin, 1223
Eating motivation, 123
amphetamine
fenfluramine
naloxone
naltrexone
satiety
EEG alpha activity, 889
ethanol-induced euphoria
human studies, males
plasma ethanol levels
Electrical stimulation, 63
DOPAC
intracranial self-stimulation
in vivo
nigro-striatal pathway
Electroencephalographic effects, 879
human studies, smokers
nicotine gum
tobacco deprivation
Electrophysiological properties, 89
cannabidiol
cats
spinal motoneurons
synaptic effects
Endogenous opiates, 1303
opiate receptor sites
peptide interactions
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
Endogenous opioids
drug interactions, 1007
naltrexone, 573
opiates, 1007
postpartum aggression, 1007
prenatal stress, 573
sexual behavior differentiation, 573
Environmental constraints, 561
defensive behavior
diazepam
fear reactions
Environmental influences, 95
GABA receptors
muricide
Environmental specific cues, 1201
analgesia
classical conditioning
habituation
morphine
snails
stress
tolerance
L-Erythro-dihydroxyphenylserine (L-erythro-DOPS), 411
brain noradrenergic system
locomotor activity

Escape deficit, 1
antidepressants
inescapable shocks
learned helplessness
serotonergic neurons
Essential fatty acids, 1285
cholesterol
dietary manipulation
ethanol preference
hamsters
retinol palmitate
Estrogen, 919
amphetamine-induced hyperactivity
time-dependent modulation
Ethanol
ambient temperature, 667
CGS 8216, 439
chronic administration, 667
classical conditioning, 35
cross tolerance, 35
drug comparisons, 1035
drug interactions, 439, 1035
ethanol withdrawal, 1111
food-deprived/free-feeding rat comparisons, 739
hypoglycemia, 739
hypothermia, 739
hypothermia, ethanol-induced, 667
indomethacin, 739
inhibition and stimulation, 1035
locomotor activity, 1035
d-methamphetamine, 1035
naltrexone, 439
Pavlovian conditioning, 1111
radial arm maze performance, 703
sex differences, 703
shock avoidance, 439
sodium pentobarbitol, 35
timeout from avoidance, 439
tolerance, 667
Ethanol effects, 607
single unit activity
somatosensory cortex
Ethanol-induced euphoria, 889
EEG alpha activity
human studies, males
plasma ethanol levels
Ethanol preference, 1285
cholesterol
dietary manipulation
essential fatty acids
hamsters
retinol palmitate
Ethanol tolerance, 797
limbic structures
serotonin synthesis
vasopressin-like peptides
Ethanol withdrawal, 1111
ethanol
Pavlovian conditioning
Exploratory activity, 255
dopamine autoreceptor agonists
locomotor activity, drug-induced, 255
Exploratory behavior
apomorphine, 473
classical conditioning, 1169
dopamine receptors, 473
drug reinforcement, 1169
habituation, 1169
morphine, 1169
neuroleptics, 473
place preference, 1169
Exponential data analysis, 979
passive avoidance
step-through latencies
Extinction
adjunctive consumption, 1159, 1163
alcohol, 1159, 1163
drinking, 1159, 1163
food reward, 813
haloperidol, 813
lithium, 1159, 1163
shock, 1163
stress, 1163
water, 1159

Fear reactions, 561
defensive behavior
diazepam
environmental constraints
Feeding behavior
2-deoxy-D-glucose, 59
dopamine metabolism, 1095
hyperphagia, 59
ingestion, 1095
lateral hypothalamus, 59
nucleus accumbens, 1095
striatum, 1095
5-thioglucose, 59
ventromedial hypothalamus, 59
Fenfluramine
amphetamine, 123
anorexia, 967
eating motivation, 123
gastrointestinal tract, 967
naloxone, 123
naltrexone, 123
opioid peptides, 967
satiety, 123
FG 7142, 99
anorexia
eating
grooming
hyperphagia
locomotor activity
midazolam
rearing
Filter vent blocking, 1245
carbon monoxide exposure
human studies
smoking topography
tobacco
Finger tapping, 727
human studies, non-smokers
nicotine
Fixed ratio/fixed interval schedule, 375
locomotor activity
pentobarbital
secobarbital
stereoisomers
variable interval schedule
Fixed ratio performance, 1191
differential reinforcement of low rate of response (DRL)
operant behavior
3-quinuclidinyl benzilate (QNB)
schedule dependent effects
Focal brain injury, 263
lateralized hyperactivity
lesions, cortical island
Food deprivation, 623
abrupt refeeding
phentermine
self-administration
Food-deprived/free feeding rat comparisons, 739
ethanol
hypoglycemia
hypothermia
indomethacin
Food hoarding, 543
deer mouse
ingestion
opiate agonists
Food intake, 913
benzodiazepines
brown adipose tissue (BAT)
cafeteria diet
food preference
Food preference, 913
benzodiazepines
brown adipose tissue (BAT)
cafeteria diet
food intake
Food reward, 813
extinction
haloperidol
Force of response, 615
anhedonia
duration of response
pimozide
response rate
Fourth ventricle, 843
cytisine
dogs
high/low affinity sites
2-methylpiperidine
nicotine
Free-choice drinking, 1013
alcohol dehydrogenase
alcohol elimination rate
alcohol-preferring rats
metabolic tolerance
Functional sensitivity, 743
α_1-adrenoceptors
β-adreoceptors
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)
noradrenergic denervation

GABA receptors, 95
environmental influences
muricide
$GABA_A$ receptors, 1059
anticonvulsant effects
bicuculline
drug interactions
maximal electroshock
pentobarbital
phenobarbital
picrotoxin
seizures
GABAergic drugs, 1077
chlordiazepoxide-induced sleep
selective breeding
Gastric ulceration, 775
cold-restraint stress
motility
Gastrointestinal tract, 967
anorexia
fenfluramine
opioid peptides
Genetic behavior, 289
genetic breeding
habituation

open-field activity
pharmacogenetics
Genetic breeding, 289
genetic behavior
habituation
open-field activity
pharmacogenetics
Glucoprivation, 1153
2-deoxy-D-glucose
hypophagia
liquid diet
water deprivation
Glucoprivic feeding, 381
appetite regulation
deprivation
eating
lesions, paraventricular nucleus (PVN)
Glycoprotein fucosylation, 1137
memory function
Grooming, 99
anorexia
eating
FG 7142
hyperphagia
locomotor activity
midazolam
rearing

H_2-receptor blockers, 511
behavioral despair test
naloxone
Habituation
acoustic startle, 1175
amphetamine, 1175
analgesia, 1201
classical conditioning, 1169, 1201
cocaine, 1175
cross-tolerance, 1175
drug reinforcement, 1169
environmental specific cues, 1201
exploratory behavior, 1169
genetic behavior, 289
genetic breeding, 289
morphine, 1169, 1201
open-field activity, 289
pharmacogenetics, 289
phencyclidine (PCP), 1175
place preference, 1169
sensitization, 1175
snails, 1201
stress, 1201
tolerance, 1175, 1201
Haloperidol
anhedonia, 1231
cocaine, 497
cyclo(leucyl-glycyl) (cLG), 1279
dopamine receptors, 1279
extinction, 813
food reward, 813
motor effects, 791
neuroleptics, 791
operant responding, 791
partial reinforcement extinction effect, 1231
reward omission, periodic, 1231
self-administration, 497
sex differences, 497
stereotypy, apomorphine-induced, 1279
supersensitivity, 1279
tamoxifen, 497
water reinforcement, 1231
Hamsters
cholecystokinin (CCK), 1067
cholesterol, 1285
clonidine, 1107
dietary manipulation, 1285
drinking, 449
eating, 1107
essential fatty acids, 1285
ethanol preference, 1285
high-calorie fluids, 449
hyperactivity, 1067
hypoactivity, 1067
morphine, 1067
reproduction, 449
retinol palmitate, 1285
social stress, 449
Harmine, 111
ketanserin
lordosis
pirenperone
Heart rate
blood pressure, 423
body temperature, 1293
chemical stimulation, 423
diisopropylfluorophosphate (DFP), 1293
locomotor activity, 1293
mediodorsal nucleus of the thalamus, 423
muscarinic receptors, 1293
^{3}H-quinuclidinyl benzilate (^{3}H-QNB) binding, 1293
rabbits, 423
respiration rate, 1293
tolerance, 1293
Heat, 1071
cholinesterase inhibition
clinical chemistry
pyridostigmine
thermoregulation
Hemicholinium-3, 925
amnesia
drug interactions
piracetam-like compounds
Hexahydrocannabinol stereochemistry, 393
drug discrimination
rat/pigeon comparisons
Hibernation, 527
bat/rat/mouse/hamster comparisons
brain opioid receptors
High-calorie fluids, 449
drinking
hamsters
reproduction
social stress
High/low affinity sites, 843
cytisine
dogs
fourth ventricle
2-methylpiperidone
nicotine
Hippocampal 5-HT activity, 781
rabbits
tonic immobility
Hormone
estradiol, 857
estradiol benzoate, 111, 919
estrogen, 857
norepinephrine (NE), 1223
progesterone, 111, 857
prostaglandin, 463
prostaglandin (PGE_1), 347, 353
testosterone, 823
Hotplate test, 933
pemoline
self-injurious behavior
stereotypy
5-HT syndrome, 873
offspring behavior
open-field behavior
prenatal stress
Human studies
buccal mucosa, 1181
carbon monoxide exposure, 1245
filter vent blocking, 1245
marijuana smoking, 659
nicotine absorption, 1181
passive smoking, 1181
smoking topography, 1245
subjective ratings, 659
tobacco, 1245
tobacco smoking, 659
Human studies, males
behavioral analysis, 577
caloric intake, 577
diphenhydramine, 365
driving related tasks, 365
eating, 577
EEG alpha activity, 889
ethanol-induced euphoria, 889
marijuana, 577
plasma ethanol levels, 889
plasma levels, 365
Human studies, non-smokers, 727
finger tapping
nicotine
Human studies, smokers, 879
electroencephalographic effects
nicotine gum
tobacco deprivation
Huntington's disease, 297
animal model
locomotor hyperactivity
neural transplants
8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT), 135
drug discrimination
ketanserin pretreatment
tetralin analogues
6-Hydroxydopamine (6-OHDA), 949
α-methyl-p-tyrosine (α-MPT)
catecholamines
seizures, pentylenetetrazol (PTZ) induced
5-Hydroxytryptamine (5-HT)
drug interactions, 23
hyperalgesia, 883
hyperdipsia, 23
hypoalgesia, 883
hypophagia, 23
methysergide, 23
nociception sensitivity, 883
8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT), 883
propranolol, 23
route of administration, 883
Hyperactivity
benzodiazepines, 1145
cholecystokinin (CCK), 1067
convulsions, 1145
hamsters, 1067
hypoactivity, 1067
morphine, 1067

neonates, 1145
type 2 receptors, 1145
Hyperactivity drug induced, 711
amphetamine
anorexia, drug induced
phenylethylamine (PEA)
Hyperalgesia, 883
5-hydroxytryptamine (5-HT)
hypoalgesia
nociception sensitivity
8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT)
route of administration
Hyperdipsia, 23
drug interactions
5-hydroxytryptamine (5-HT)
hypophagia
methysergide
propranolol
Hyperphagia
analgesia, stress-induced, 171
anorexia, 99
brain monoamines, 401
cold water swim, 171
2-deoxy-D-glucose, 59
eating, 99
feeding behavior, 59
FG 7142, 99
grooming, 99
hypothermia, 171
lateral hypothalamus, 59
lesions, medial hypothalamus, 401
locomotor activity, 99
midazolam, 99
muscarinic agents, 171
obesity, 401
pain, 171
rearing, 99
5-thioglucose, 59
ventromedial hypothalamus, 59
Hypertension, 317
lesions, substantia nigra
open field
strain differences
striatal dopamine content
Hyperthermia, 555
calcium channel antagonists
drug interactions
thermoregulation
Hypoactivity, 1067
cholecystokinin (CCK)
hamsters
hyperactivity
morphine
Hypoalgesia, 883
5-hydroxytryptamine (5-HT)
hyperalgesia
nociception sensitivity
8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT)
Hypocaloric diets, 681
insulin receptors
obesity
simple carbohydrate comparisons
Hypoglycemia, 739
ethanol
food-deprived/free-feeding rat comparisons
hypothermia
indomethacin
Hypophagia
2-deoxy-D-glucose, 1153
drug interactions, 23
glucoprivation, 1153
5-hydroxytryptamine (5-HT), 23
hyperdipsia, 23
liquid diet, 1153
methysergide, 23
propranolol, 23
water deprivation, 1153
Hypothermia
adenosine receptors, 769
analgesia, stress-induced, 171
cold water swim, 171
ethanol, 739
food-deprived/free-feeding rat comparisons, 739
hyperphagia, 171
hypoglycemia, 739
inbred strains, 769
indomethacin, 739
locomotor activity, 769
methylxanthines, 769
muscarinic agents, 171
pain, 171
theobromine, 769
Hypothermia, ethanol-induced, 667
ambient temperature
chronic administration
ethanol
tolerance

Imipramine, 149
drug interactions
methadone
pigeons
variable interval schedule
Immobilization, acute, 41
neurobiological responses
social isolation
Inbred strains, 769
adenosine receptors
hypothermia
locomotor activity
methylxanthines
theobromine
Indomethacin, 739
ethanol
food-deprived/free-feeding rat comparisons
hypoglycemia
hypothermia
Inescapable shock, 1
antidepressants
escape deficit
learned helplessness
serotonergic neurons
Ingestion
deer mouse, 543
dopamine metabolism, 1095
feeding behavior, 1095
food hoarding, 543
nucleus accumbens, 1095
opiate agonists, 543
striatum, 1095
Inhibition and stimulation, 1035
drug comparisons
drug interactions
ethanol
locomotor activity
d-methamphetamine
Inhibitory avoidance, 469
avoidance learning
substance P
Insulin receptors, 681
hypocaloric diets
obesity
simple carbohydrate comparisons
Internal clock speed, 1185
D_2 receptors
dopamine
neuroleptics
time estimation
Inter-response time, 145
d-amphetamine
bin analysis
monkeys
Sidman avoidance schedule
Intestinal distention, 491
acarbose
dietary starch
Intracerebral cannula, 487
rodents, small
unrestrained animals
Intracranial administration, 717
lysergic acid diethylamide (LSD)
operant behavior
route of administration
Intracranial self-stimulation, 63
DOPAC
electrical stimulation
in vivo
nigro-striatal pathway
Intraspecies behavior, 515
antidepressants
locomotor activity
pharmaco-ethological analysis
Intrathecal injection, 483
chronic infusion
tolerance
Investigatory behavior, 277
locomotor activity
multivariate assessment
stimulants
In vitro, 827
metabolic interactions
phencyclidine (PCP)
Ca^{++}-precipitated liver microsomes
Δ^9-tetrahydrocannabinol (Δ^9-THC)
In vivo
alpha$_2$-adrenergic antagonists, 155
amphetamine, 155
DOPAC concentrations, 63
electrical stimulation, 63
intracranial self-stimulation, 63
locomotor activity, 155
nafion-coated electrodes, 325
nigro-striatal pathway, 63
stereotypy, 155
voltammetric recording, 325
Isocaloric diets, 7
bombesin
cholecystokinin (CCK)
dietary self-selection

Ketanserin, 111
harmine
lordosis
pirenperone
Ketanserin pretreatment, 135
drug discrimination
8-hydroxy-2-(di-n-propylamino) tetralin (8-OH DPAT)
tetralin analogues

Lateral hypothalamus, 59
2-deoxy-D-glucose
feeding behavior
hyperphagia
5-thioglucose
ventromedial hypothalamus
Lateralized hyperactivity, 263
focal brain injury
lesions, cortical island
Lateralized rotation, 689
apomorphine
postural asymmetry
Lead retention, 1089
behavioral development
preweaning lead exposure
Learned helplessness, 1
antidepressants
escape deficit
inescapable shock
serotonergic neurons
Learning, 141
brain iron-deficiency
water maze
Lesions, cortical island, 263
focal brain injury
lateralized hyperactivity
Lesions, dorsal raphe nucleus, 1211
lesions, locus coeruleus
lesions, medial raphe nucleus
locomotor activity
open field
α_1-receptors
sedation, clonidine-induced
Lesions, 6-hydroxydopamine (6-OHDA), 1307
amphetamine
dopamine depletion
lesions, substantia nigra
recovery
rotation
Lesions, kainic acid, 583
barrel rotation, 583, 589
behavioral changes, 589
nicotine, 583
prostration, 583
receptor changes, 589
vasopressin, 583
vestibular cerebellum, 583
Lesions, locus coeruleus, 1211
lesions, dorsal raphe nucleus
lesions, medial raphe nucleus
locomotor activity
open field
α_1-receptors
sedation, clonidine-induced
Lesions, medial hypothalamus, 401
brain monoamines
hyperphagia
obesity
Lesions, medial raphe nucleus, 1211
lesions, dorsal raphe nucleus
lesions, locus coeruleus
locomotor activity
open field
α_1-receptors
sedation, clonidine-induced
Lesions, neurotoxic, 191
cocaine
medial prefrontal cortex
presynaptic dopaminergic terminals
self-administration, intracranial
Lesions, nucleus basalis magnocellularis, 293
diurnal cycle
locomotor activity
Lesions, paraventricular nucleus (PVN), 381
appetite regulation
deprivation
eating
glucoprivic feeding
Lesions, substantia nigra
amphetamine, 1307
dopamine depletion, 1307
hypertension, 317
lesions, 6-hydroxydopamine (6-OHDA), 1307
open field, 317
recovery, 1307
rotation, 1307
strain differences, 317
striatal dopamine content, 317
Lever pressing, 973
conditioned aversions
drug-paired stimuli
lithium chloride (LiCl)
monkeys
Licking, 219
anhedonia
pimozide
sucrose concentration
Limbic structures, 797
ethanol tolerance
serotonin synthesis
vasopressin-like peptides
Limbic system, 71
aggression
bull breeds
neurotransmitter amino acids
Liquid diet, 1153
2-deoxy-D-glucose
glucoprivation
hypophagia
water deprivation
Lithium
adjunctive consumption, 1159, 1163
alcohol, 1159, 1163
drinking, 1159, 1163
extinction, 1159, 1163
shock, 1163
stress, 1163
water, 1159
Lithium-chloride (LiCl), 973
conditioned aversions
drug-paired stimuli
lever pressing
monkeys
Locomotor activity
acetylcholine release, 943
adenosine receptors, 769
alpha$_2$-adrenergic antagonists, 155
age differences, 599
amphetamine, 155, 161, 1149
anorexia, 99
antidepressants, 515
antinociception, 599
anxiety, 595
area postrema, 269
atropine, 985
body temperature, 1293
brain noradrenergic system, 411
caffeine, 1271
circling behavior, 1021
clonidine, 985
conditioned place aversion, 1041
conditioned place preference, 1041
conditioned taste aversion, 269
convulsions, 595
diisopropylfluorophosphate (DFP), 1293
6,7-dimethoxy, 4 ethyl β-carboline carboxylic acid methyl ester (DMCM), 595
diurnal cycle, 293
drug comparisons, 1035
drug interactions, 943, 985, 1035
eating, 99, 1149
L-erythro-dihydroxyphenylserine (L-erythro-DOPS), 411
ethanol, 1035
fixed ratio/fixed interval schedule, 375
FG 7142, 99
grooming, 99
heart rate, 1293
hyperphagia, 99
hypothermia, 769
inbred strains, 769
inhibition and stimulation, 1035
intraspecies behavior, 515
investigatory behavior, 277
in vivo, 155
lesions, dorsal raphe nucleus, 1211
lesions, locus coeruleus, 1211
lesions, medial raphe nucleus, 1211
lesions, nucleus basalis magnocellularis, 293
metabolic rate, 161
d-methamphetamine, 1035
N-methyl aspartate, 943
methylxanthines, 769
midazolam, 99
morphine, 599
multivariate assessment, 277
muscarinic receptors, 1293
naltrexone, 595
nicotine, 1041
nucleus accumbens, 1149
open field, 1211
pentobarbital, 375
pharmaco-ethological analysis, 515
prenatal alcohol exposure, 1021
propunishment, 595
^{3}H-quinuclidinyl benzilate (^{3}H-QNB) binding, 1293
rearing, 99
α_1-receptors, 1211
respiration rate, 1293
scopolamine, 269
secobarbital, 375
sedation, clonidine-induced, 1211
stereoisomers, 375
stereotypy, 155, 985
stimulants, 277
strain differences, 1271
theobromine, 769
theophylline, 1271
tolerance, 1293
variable interval schedule, 375
Locomotor activity, drug-induced, 255
dopamine autoreceptor agonists
exploratory activity
Locomotor behavior, 233
opiates
psychostimulants
sympathomimetics

Locomotor excitation, 29
alternation
amphetamine
perseveration
Locomotor hyperactivity, 297
animal model
Huntington's disease
neural transplants
Lordosis, 111
harmine
ketanserin
pirenperone
Lordosis disruption, 857
midbrain infusions
procaine
tetrodotoxin
LY 171555, 1117
dopamine systems
radial arm maze
Lysergic acid diethylamide (LSD)
intracranial administration, 717
operant behavior, 717
pizotyline, 227
route of administration, 717
stimulus control, 227
verapamil, 227

Magnesium, 1195
acute administration
aggression
chronic administration
tolerance
Marijuana
adrenergic receptors, 763
behavioral analysis, 577
caloric intake, 577
dopamine receptors, 763
eating, 577
human studies, males, 577
perinatal exposure, 763
tyrosine hydroxylase activity, 763
Marijuana smoking, 659
human studies
subjective rating
tobacco smoking
Maximal electroshock, 1059
anticonvulsant effects
bicuculline
drug interactions
$GABA_A$ receptors
pentobarbital
phenobarbital
picrotoxin
seizures
Maze learning, 673
age differences
avoidance conditioning
memory
scopolamine
Medial hypothalamus, 1223
deprivation
eating
norepinephrine (NE)
paraventricular nucleus (PVN)
serotonin
Medial prefrontal cortex, 191
cocaine
lesions, neurotoxic
presynaptic dopaminergic terminals
self-administration, intracranial

Mediodorsal nucleus of the thalamus, 423
blood pressure
chemical stimulation
heart rate
rabbits
Memory
age differences, 673
avoidance conditioning, 673
chicks, 823
maze learning, 673
scopolamine, 673
testosterone, 823
Memory effects, time related, 1125
consolidation
passive avoidance behavior
retrieval
vasopressin
vasopressin analogues
Memory function, 1137
glycoprotein fucosylation
Metabolic interactions, 827
in vitro
phencyclidine (PCP)
Ca^{++}-precipitated liver microsomes
Δ^9-tetrahydrocannabinol (Δ^9-THC)
Metabolic rate, 161
amphetamine
locomotor activity
Metabolic tolerance, 1013
alcohol dehydrogenase
alcohol elimination rate
alcohol-preferring rats
free-choice drinking
Metazocine, 785
drug discrimination
monkeys
self-administration
stimulus properties
Methadone, 149
drug interactions
imipramine
pigeons
variable interval schedule
d-Methamphetamine, 1035
drug comparisons
drug interactions
ethanol
inhibition and stimulation
locomotor activity
[D-Ala^2]-Methionine enkephalinamide (DALA), 641
anesthesia
antinociception
cardiovascular system
renal sympathetic nerve
Method
autoradiography, 1051
Behavioral Pattern Monitor, 277
color tracing, 117
formalin test, 883
gas chromatography, 827
high performance liquid chromatography (HPLC), 415, 865, 903
hot-plate test, 883
kainate lesioning, 583, 589
key peck, 371
pendulum technique, 329
platform technique, 329
radio-frequency lesions, 1279
Sidman avoidance schedule, 145
tail-flick test, 883

5-Methoxy-N,N-dimethyltryptamine (5-OMe DMT), 1207
dose-dependent effects
drug discrimination
Sidman avoidance schedule, 145
serotonin antagonists
stimulus properties
2-Methylpiperidone, 843
cytisine
dogs
fourth ventricle
high/low affinity sites
nicotine
α-Methyl-p-tyrosine (α-MPT), 949
catecholamines
6-hydroxydopamine (6-OHDA)
seizures, pentylenetetrazol (PTZ) induced
Methylxanthines, 769
adenosine receptors
hypothermia
inbred strains
locomotor activity
theobromine
Methysergide, 23
drug interactions
5-hydroxytryptamine (5-HT)
hyperdipsia
hypophagia
propranolol
Midazolam, 99
anorexia
eating
FG 7142
grooming
hyperphagia
locomotor activity
rearing
Midbrain infusions, 857
lordosis disruption
procaine
tetrodotoxin
Model of depression, 805
antidepressants
serotonergic receptors
Monkeys
d-amphetamine, 145
bin analysis, 145
conditioned aversions, 973
delayed performance, 201
drug discrimination, 785
drug interactions, 185
drug-paired stimuli, 973
inter-response time, 145
lever pressing, 973
lithium chloride (LiCl), 973
metazocine, 785
nicotine, 185
phencyclidine (PCP), 185, 201
repeated acquisitions, 185, 201
response chains, 185, 201
retention, 201
self-administration, 785
Sidman avoidance schedule, 145
stimulus properties, 785
Morphine
age differences, 599
analgesia, 215, 1201
antinociception, 599, 835
antinociceptive system, 533
benzodiazepine receptors, 215
cholecystokinin (CCK), 1067

classical conditioning, 1169, 1201
conditioned place preference, 1101
drinking, 1001
drug comparisons, 835
drug discrimination, 209
drug interactions, 835
drug reinforcement, 1101, 1169
environmental specific cues, 1201
exploratory behavior, 1169
habituation, 1169, 1201
hamsters, 1067
hyperactivity, 1067
hypoactivity, 1067
locomotor activity, 599
naloxone antagonism, 209
naloxone-precipitated withdrawal, 1001
opiate tolerance, 533
physical dependence, 1001
pigeons, 209
place preference, 1169
reinforcement threshold, 1263
response rate, 1263
self-stimulation, 1263
single-trial, 1101
snails, 1201
stimulation-produced analgesia, 533
stress, 1201
sucrose, 1001
tizanidine, 835
tolerance, 835, 1201
withdrawal, precipitated, 1263
withdrawal, spontaneous, 1263
Morphine dependent rats, 953
angiotensin converting enzyme (ACE) activity
aspartic acid
brain asparaginase
naloxone
plasma cortisol level
Motility, 775
cold-restraint stress
gastric motility
Motor activity
calcium antagonists, 45
chronic administration, 129
dopamine receptors, 129
drug interactions, 45
phencyclidine (PCP), 45
phenylethylamine (PEA), 129
sensitization, 129
Motor effects, 791
haloperidol
neuroleptics
operant responding
MSH-release inhibiting factor-1 (MIF-1), 757
apomorphine-induced stereotypy
dopaminergic neuron activity
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
apomorphine-induced stereotypy, 757
dopaminergic neuron activity, 757
endogenous opiates, 1303
MSH-release inhibiting factor-1 (MIF-1), 757
opiate receptor sites, 1303
peptide interactions, 1303
Multivariate assessment, 277
investigatory behavior
locomotor activity
stimulants
Muricide, 95
environmental influences
GABA receptors
Muscarinic agents, 171
analgesia, stress-induced
cold water swim
hyperphagia
hypothermia
pain
Muscarinic receptors, 1293
body temperature
diisopropylfluorophosphate (DFP)
heart rate
locomotor activity
^{3}H-quinuclidinyl benzilate (^{3}H-QNB) binding
respiration rate
tolerance

Nafion-coated electrodes, 325
in vivo
voltammetric recording
Nalbuphine, 629
brain stimulation
drug interactions
reward threshold
tripelennamine
Naloxone
adrenergic receptors, 989
amnesia, 567
amphetamine, 123
angiotensin converting enzyme (ACE) activity, 953
anisomycin, 567
aspartic acid, 953
behavioral despair test, 511
brain asparaginase, 953
clonidine, 989
continuous infusion, 989
cycloheximide, 567
drinking, 697
drug interactions, 567, 989
eating motivation, 123
fenfluramine, 123
H_3-receptor blockers, 511
morphine dependent rats, 953
naltrexone, 123
opiate abstinence syndrome, 989
palatability, 697
passive avoidance, 567
plasma cortisol level, 953
satiation, 697
sequential presentation, 697
shuttle avoidance, 567
Naloxone antagonism, 209
drug discrimination
morphine
pigeons
Naloxone-precipitated withdrawal, 1001
drinking
morphine
physical dependence
sucrose
Naltrexone
amphetamine, 123
anxiety, 595
CGS 8216, 439
convulsions, 595
6,7-dimethoxy, 4 ethyl β-carboline carboxylic acid methyl ester (DMCM), 595
drug interactions, 439
eating motivation, 123
endogenous opioids, 573
ethanol, 439
fenfluramine, 123
locomotor activity, 595
naloxone, 123
prenatal stress, 573
propunishment, 595
satiety, 123
sexual behavior differentiation, 573
shock avoidance, 439
timeout from avoidance, 439
Neonates, 1145
benzodiazepines
convulsions
hyperactivity
type 2 receptors
Neural transplants, 297
animal model
Huntington's disease, 297
locomotor hyperactivity, 297
Neurobiological responses, 41
immobilization, acute
social isolation
Neuroleptics
apomorphine, 473, 503
behavioral deficits, 503
cataleptic behavior, 463
cognitive deficits, 503
D_2 receptors, 1185
dopamine, 1185
dopamine receptors, 473
drug interactions, 463
exploratory behavior, 473
haloperidol, 791
internal clock speed, 1185
motor effects, 791
operant behavior, 503
operant responding, 791
prostaglandins, 463
time estimation, 1185
Neurotransmitter amino acids, 71
aggression
bull breeds
limbic system
Nicotine
barrel rotation, 583
body weight, 1131
caloric intake, 1131
conditioned place aversion, 1041
conditioned place preference, 1041
cytisine, 843
dogs, 843
drug interactions, 185
finger tapping, 727
fourth ventricle, 843
high/low affinity sites, 843
human studies, non-smokers, 727
lesions, kainic acid, 583
locomotor activity, 1041
2-methylpiperidone, 843
monkeys, 185
phencyclidine (PCP), 185
physical activity, 1131
prostration, 583
rats, females, 1131
repeated acquisition, 185
response chain, 185

vasopressin, 583
vestibular cerebellum, 583
Nicotine absorption, 1181
buccal mucosa
human studies
passive smoking
Nicotine gum, 879
electroencephalographic effects
human studies, smokers
tobacco deprivation
Nigro-striatal pathway, 63
DOPAC concentrations
electrical stimulation
intracranial self-stimulation
in vivo
Nociception sensitivity, 883
5-hydroxytryptamine
hyperalgesia
hypoalgesia
8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT)
route of administration
Noradrenergic denervation, 743
α_1-adrenoceptors
β-adrenoceptors
functional sensitivity
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)
Norepinephrine (NE)
adenylate cyclase, 223
^{3}H-cyclic AMP, 223
deprivation, 1223
eating, 1223
medial hypothalamus, 1223
paraventricular nucleus (PVN), 1223
REM sleep deprivation, 223
serotonin, 1223
Nucleus accumbens
amphetamine, 1149
dopamine metabolism, 1095
eating, 1149
feeding behavior, 1095
ingestion, 1095
locomotor activity, 1149
striatum, 1095

Obesity
brain monoamines, 401
hyperphagia, 401
hypocaloric diets, 681
insulin receptors, 681
lesions, medial hypothalamus, 401
simple carbohydrate comparisons, 681
Offspring behavior, 873
5-HT syndrome
open-field behavior
prenatal stress
8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT), 883
5-hydroxytryptamine (5-HT)
hyperalgesia
hypoalgesia
nociception sensitivity
route of administration
Open field
hypertension, 317
lesions, dorsal raphe nucleus, 1211
lesions, locus coeruleus, 1211
lesions, medial raphe nucleus, 1211
lesions, substantia nigra, 317
locomotor activity, 1211
α_2-receptors, 1211
sedation, clonidine induced, 1211
strain differences, 317
striatal dopamine content, 317
Open-field activity, 289
genetic behavior
genetic breeding
habituation
pharmacogenetics
Open-field behavior, 873
5-HT syndrome
offspring behavior
prenatal stress
Operant behavior
apomorphine, 503
behavioral deficits, 503
cognitive deficits, 503
differential reinforcement of low rate of response (DRL), 1191
fixed ratio performance, 1191
intracranial administration, 717
lysergic acid diethylamide (LSD), 717
neuroleptics, 503
3-quinuclidinyl benzilate (QNB), 1191
route of administration, 717
schedule dependent effects, 1191
Operant responding, 791
haloperidol
motor effects
neuroleptics
Opiate abstinence syndrome, 989
adrenergic receptors
clonidine
continuous infusion
drug interactions
naloxone
Opiate agonists, 543
deer mouse
food hoarding
ingestion
Opiate receptor sites, 1303
endogenous opiates
peptide interactions
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
Opiate receptors, 959
circling, opiate-induced
dopaminergic system
ventral tegmental area
Opiate tolerance, 533
antinociceptive system
morphine
stimulation-produced analgesia
Opiates
drug interactions, 1007
endogenous opiates, 1007
locomotor behavior, 233
postpartum aggression, 1007
psychostimulants, 233
sympathomimetics, 233
Opioid agonists, 77
drinking
water balance
Opioid peptides, 967
anorexia
fenfluramine
gastrointestinal tract
Oxytocin, 107
corticosterone
psychological stressor

P-chlorophenylalanine (PCPA), 415
shock, uncontrollable
stress
Pain, 171
analgesia, stress-induced
cold water swim
hyperphagia
hypothermia
muscarinic agents
Palatability, 697
drinking
naloxone
satiation
sequential presentation
Paraventricular nucleus (PVN), 1223
deprivation
eating
medial hypothalamus
norepinephrine (NE)
serotonin
Partial reinforcement extinction effect, 1231
anhedonia
haloperidol
reward omission, periodic
water reinforcement
Passive avoidance
amnesia, 567
anisomycin, 567
cycloheximide, 567
drug interactions, 567
exponential data analysis, 979
naloxone, 567
shuttle avoidance, 567
step-through latencies, 979
Passive avoidance behavior, 1125
consolidation
memory effects, time related
retrieval
vasopressin
vasopressin analogues
Passive smoking, 1181
buccal mucosa
human studies
nicotine absorption
Pavlovian conditioning, 1111
ethanol
ethanol withdrawal
^{3}H-PCP binding potency, 1051
autoradiography
discriminative stimulus properties
phencyclidine (PCP)-related compounds
Pemoline, 933
hotplate test
self-injurious behavior
stereotypy
Pentobarbital
anticonvulsant effects, 1059
bicuculline, 1059
drug interactions, 1059
fixed ratio/fixed interval schedule, 375
$GABA_A$ receptors, 1059
locomotor activity, 375
maximal electroshock, 1059
phenobarbital, 1059
picrotoxin, 1059
secobarbital, 375
seizures, 1059
stereoisomers, 375
variable interval schedule, 375

Peptide
adrenocorticotropic hormone 1–24 (ACTH 1–24), 753, 1303
adrenocorticotropic hormone 1–39 (ACTH 1–39), 1303
alpha-methyl-p-tyrosine, 959
arginine vasopressin (AVP), 797, 1125
arginine vasopressin (1–8) (AVP-(1–8)), 1125
arginine vasopressin (4–8) (AVP-(4–8)), 1125
arginine vasopressin (4–9) (AVP-(4–9)), 1125
arginine vasopressin (5–8) (AVP-(5–8)), 1125
arginine vasopressin (5–9) (AVP-(5–9)), 1125
bombesin, 7
cholecystokinin (CCK), 7, 1067
cholecystokinin octapeptide (CCK-8), 1303
cyclo(leucyl-glycyl) (cLG), 1279
d-Ala(2)-d-Leu(5)-enkephalin (DADLE), 959
[D-Pen^2,D-Pen^5-enkephalin] (DPDPE), 77, 1303
desglycinamide-arginine-vasopressin (DGAVP), 797
dynorphin (1–13), 77, 959
FMRF-NH_2, 1303
morphiceptin, 1303
MSH-release inhibiting factor-1 (MIF-1), 757, 1303
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1), 757, 1303
substance P, 469
(Tyr-D-Ala-Gly-(Me)Phe-Gly-ol) (DAGO), 1303
(Tyr-D-Ala-Gly-(Me)Phe-Met-ol) (FK33824), 1303
vasopressin, 583, 589
Peptide interactions, 1303
endogenous opiates
opiate receptor sites
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
Perinatal exposure, 763
adrenergic receptors
dopamine receptors
marijuana
tyrosine hydroxylase activity
Perioral behaviors, 1217
cholinesterase inhibitors
physostigmine
tardive dyskinesia
Perseveration, 29
alternation
amphetamine
locomotor excitation
Pharmaco-ethological analysis, 515
antidepressants
intraspecies behavior
locomotor activity
Pharmacogenetics, 289
genetic behavior
genetic breeding
habituation
open-field activity
Phencyclidine (PCP)
acoustic startle, 1175
amphetamine, 1175
calcium antagonists, 45
cocaine, 1175
cross-tolerance, 1175
delayed performance, 201
drug discrimination, 117
drug interactions, 45, 185
habituation, 1175
in vitro, 827
metabolic interactions, 827
monkeys, 185, 201
motor activity, 45
nicotine, 185
pigeons, 117
plasma phencyclidine, 117
Ca^{++}-precipitated liver microsomes, 827
repeated acquisition, 185, 201
response chains, 185, 201
retention, 201
sensitization, 1175
Δ^9-tetrahydrocannabinol (Δ^9-THC), 827
tolerance, 1175
Phencyclidine (PCP) metabolites, 359
age differences
cats
tolerance
Phencyclidine (PCP)-related compounds, 1051
autoradiography
discriminative stimulus properties
^{3}H-PCP binding potency
Phenobarbital
anticonvulsant effects, 1059
bicuculline, 1059
delayed-matching-to-sample, 929
drug interactions, 929, 1059
$GABA_A$ receptors, 1059
maximal electroshock, 1059
pentobarbital, 1059
phenytoin, 929
picrotoxin, 1059
seizures, 1059
valproic acid, 929
Phentermine, 623
abrupt feeding
food deprivation
self-administration
Phenylethylamine (PEA)
amphetamine, 711
anorexia, drug induced, 711
chronic administration, 129
dopamine receptors, 129
hyperactivity, drug induced, 711
motor activity, 129
sensitization, 129
Phenytoin, 929
delayed-matching-to-sample
drug interactions
phenobarbital
valproic acid
Physical activity, 1131
body weight
caloric intake
nicotine
rats, females
Physical dependence, 1001
drinking
morphine
naloxone-precipitated withdrawal
sucrose
Physostigmine, 1217
cholinesterase inhibitors
perioral behaviors
tardive dyskinesia
Picrotoxin, 1059
anticonvulsive effects
bicuculline
drug interactions
$GABA_A$ receptors
maximal electroshock
pentobarbital
phenobarbital
seizures
Pigeons
anxiety, 371
anxiolytic drugs, 371
beta-blockers, 371
delayed-matching-to-sample, 929
drug discrimination, 117, 209
drug interactions, 149, 929
imipramine, 149
methadone, 149
morphine, 209
naloxone antagonism, 209
phencyclidine (PCP), 117
phenobarbital, 929
phenytoin, 929
plasma phencyclidine, 117
punished responding, 371
variable interval schedule, 149
Pimozide
anhedonia, 219, 615
duration of response, 615
force of response, 615
licking, 219
response rate, 615
sucrose concentration, 219
Piracetam-like compounds, 925
amnesia
drug interactions
hemicholinium-3
Pirenperone, 111
harmine
ketanserin
lordosis
Pizotyline, 227
lysergic acid diethylamide (LSD)
stimulus control
verapamil
Place preference, 1169
classical conditioning
drug reinforcement
exploratory behavior
habituation
morphine
Plasma cortisol level, 953
angiotensin converting enzyme (ACE) activity
aspartic acid
brain asparaginase
morphine dependent rats
naloxone
Plasma ethanol levels, 889
EEG alpha activity
ethanol-induced euphoria
human studies
Plasma levels, 365
diphenhydramine
driving related tasks
human studies, males
Plasma phencyclidine, 117
drug discrimination
phencyclidine (PCP)
pigeons

Polydipsia, 431
benzodiazepines
conditioned taste aversion
drinking
two-bottle choice paradigm
Postpartum aggression, 1007
drug interactions
endogenous opioids
opiates
Postural asymmetry, 689
apomorphine
lateralized rotation
^{3}H-Prazosin, 329
adrenoceptors
antidepressants
^{3}H-dihydroalprenolol (^{3}H-DHA) binding
REM sleep deprivation
Ca^{++}-Precipitated liver microsomes, 827
in vitro
metabolic interactions
phencyclidine (PCP)
Δ^9-tetrahydrocannabinol (Δ^9-THC)
Prenatal alcohol exposure, 1021
circling behavior
locomotor activity
Prenatal stress
endogenous opioids, 573
5-HT syndrome, 873
naltrexone, 573
offspring behavior, 873
open-field behavior, 873
sexual behavior differentiation, 573
Presynaptic dopaminergic terminals, 191
cocaine
lesions, neurotoxic
medial prefrontal cortex
self-administration, intracranial
Preweaning lead exposure, 1089
behavioral development
lead retention
Procaine, 857
lordosis disruption
midbrain infusions
tetrodotoxin
Prolactin secretion, 457
buspirone
corticosterone secretion
stress
Propranolol, 23
drug interactions
5-hydroxytryptamine (5-HT)
hyperdipsia
hypophagia
methysergide
Propunishment, 595
anxiety
convulsions
6,7-dimethoxy, 4 ethyl β-carboline carboxylic acid methyl ester (DMCM)
locomotor activity
naltrexone
Prostaglandins
cataleptic behavior, 463
drug interactions, 463
neuroleptics, 463
pyrexia, 347
subdiencephalic rat brain, 347
Prostaglandin (PGE_1), 353
cochlear nucleus
pyrexia
Prostration, 583
barrel rotation
lesions, kainic acid
nicotine
vasopressin
vestibular cerebellum
Psychological stressor, 107
corticosterone
oxytocin
Psychostimulants, 233
locomotor behavior
opiates
sympathomimetics
Punished responding, 371
anxiety
anxiolytic drugs
beta-blockers
pigeons
Purine nucleotide binding, 733
appetite suppressants
brown adipose tissue (BAT)
Pyrexia
cochlear nucleus, 353
prostaglandin, 347
prostaglandin (PGE_1), 353
subdiencephalic rat brain, 347
Pyridostigmine, 1071
cholinesterase inhibition
clinical chemistry
heat
thermoregulation

3-Quinuclidinyl benzilate (QNB), 1191
differential reinforcement of low rate of response (DRL)
fixed ratio performance
operant behavior
schedule dependent effects
^{3}H-Quinuclidinyl benzilate (^{3}H-QNB) binding, 1293
body temperature
diisopropylfluorophosphate (DFP)
heart rate
locomotor activity
muscarinic receptors
respiration rate
tolerance

Rabbits
analgesiometry, 481
blood pressure, 423
chemical stimulation, 423
ear-withdrawal, 481
heart rate, 423
hippocampal 5-HT activity, 781
mediodorsal nucleus of the thalamus, 423
tonic immobility, 781
Radial arm maze, 1117
dopamine systems
LY 171555
Radial arm maze performance, 703
ethanol
sex differences
Radial maze performance, 521
BW813U
choline acetyltransferase (ChAT) inhibitor
spatial memory
Rapid eye movement (REM) sleep, 1253
cholinomimetics
chronic microinfusion
Rat/pigeon comparisons, 393
drug discrimination
hexahydrocannabinol stereochemistry
Rats, females, 1131
body weight
caloric intake
nicotine
physical activity
Rearing, 99
anorexia
eating
FG 7142
grooming
hyperphagia
locomotor activity
midazolam
Receptor changes, 589
barrel rotation
behavioral changes
lesions, kainic acid
α_2-Receptors, 1211
lesions, dorsal raphe nucleus
lesions, locus coeruleus
lesions, medial raphe nucleus
locomotor activity
open field
sedation, clonidine induced
Recovery, 1307
amphetamine
dopamine depletion
lesions, 6-hydroxydopamine (6-OHDA)
lesions, substantia nigra
rotation
Reinforcement threshold, 1263
morphine
response rate
self-stimulation
withdrawal, precipitated
withdrawal, spontaneous
REM sleep deprivation
adenylate cyclase, 223
adrenoceptors, 329
antidepressants, 329
^{3}H-cyclic AMP, 223
^{3}H-dihydroalprenolol (^{3}H-DHA) binding
norepinephrine (NE), 223
^{3}H-prazosin, 329
Renal sympathetic nerve, 641
anesthesia
antinociception
cardiovascular system
[D-Ala^2]-methionine enkephalinamide (DALA)
Repeated acquisition
delayed performance, 201
drug interactions, 185
monkeys, 185, 201
nicotine, 185
phencyclidine (PCP), 185, 201
response chains, 185, 201
retention, 201
Reproduction, 449
drinking
hamsters
high-caloric-fluids
social stress

Respiration rate, 1293
body temperature
diisopropylfluorophosphate (DFP)
heart rate
locomotor activity
muscarinic receptors
^{3}H-quinuclidinyl benzilate (^{3}H-QNB) binding
tolerance
Response bias, 633
delayed response
discrimination
scopolamine
working memory
Response chains
delayed performance, 201
drug interactions, 185
monkeys, 185, 201
nicotine, 185
phencyclidine (PCP), 185, 201
repeated acquisition, 185, 201
retention, 201
Response rate, 615
anhedonia, 615
duration of response, 615
force of response, 615
morphine, 1263
pimozide, 615
reinforcement threshold, 1263
self-stimulation, 1263
withdrawal, precipitated, 1263
withdrawal, spontaneous, 1263
Restraint stress, 1083
ulcer proliferation
voluntary ethanol consumption
Retention, 201
delayed performance
monkeys
phencyclidine (PCP)
repeated acquisition
response chains
Retinol palmitate, 1285
cholesterol
dietary manipulation
essential fatty acids
ethanol preference
hamsters
Retrieval, 1125
consolidation
memory effects, time related
passive avoidance behavior
vasopressin
vasopressin analogues
Reverse handedness, 651
appetitive learning
brain DNA
DNA synthesis
Reward omission, periodic, 1231
anhedonia
haloperidol
partial reinforcement extinction effect
water reinforcement
Reward threshold, 629
brain stimulation
drug interactions
nalbuphine
tripelennamine, 629
Rodents, small, 487
intracerebral cannula
unrestrained animals
Rotation, 1307
amphetamine
dopamine depletion
lesions, 6-hydroxydopamine (6-OHDA)
lesions, substantia nigra
recovery
Route of administration
5-hydroxytryptamine, 883
hyperalgesia, 883
hypoalgesia, 883
intracranial administration, 717
lysergic acid diethylamide (LSD), 717
nociception sensitivity, 883
8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT), 883
operant behavior, 717

Saccharin consumption, 341
CGS 8216
drinking
Satiation, 697
drinking
naloxone
palatability
sequential presentation
Satiety, 123
amphetamine
eating motivation
fenfluramine
naloxone
naltrexone
Schedule-controlled behavior, 537
benzodiazepine antagonists
drug interactions
Schedule dependent effects, 1191
differential reinforcement of low rate of response (DRL)
fixed ratio performance
operant behavior
3-quinuclidinyl benzilate (QNB)
Scopolamine
age differences, 673
area postrema, 269
avoidance conditioning, 673
conditioned taste aversion, 269
delayed response, 633
discrimination, 633
locomotor activity, 269
maze learning, 673
memory, 673
response bias, 633
working memory, 633
Secobarbital, 375
fixed ratio/fixed interval schedule
locomotor activity
pentobarbital
stereoisomers
variable interval schedule
Sedation, clonidine-induced, 1211
lesions, dorsal raphe nucleus
lesions, locus coeruleus
lesions, medial raphe nucleus
locomotor activity
open field
α_1-receptors
Sedation hypnosis, 333
circadian rhythm
sleep time
strain differences
Seizures, 1059
anticonvulsant effects
bicuculline
drug interactions
$GABA_A$ receptors
maximal electroshock
pentobarbital
phenobarbital
picrotoxin
Seizures, pentylenetetrazol (PTZ) induced, 949
catecholamines
6-hydroxydopamine (6-OHDA)
α-methyl-p-tyrosine (α-MPT)
Selective breeding, 1077
chlordiazepoxide-induced sleep
GABAergic drugs
Self-administration
abrupt refeeding, 623
cocaine, 497
drug discrimination, 785
food deprivation, 623
haloperidol, 497
metazocine, 785
monkeys, 785
phentermine, 623
sex differences, 497
stimulus properties, 785
tamoxifen, 497
Self-administration, intracranial, 191
cocaine
lesions, neurotoxic
medial prefrontal cortex
presynaptic dopaminergic terminals
Self-injurious behavior, 933
hotplate test
pemoline
stereotypy
Self-stimulation, 1263
morphine
reinforcement threshold
response rate
withdrawal, precipitated
withdrawal, spontaneous
Sensitization
acoustic startle, 1175
amphetamine, 1175
chronic administration, 129
cocaine, 1175
cross-tolerance, 1175
dopamine receptors, 129
habituation, 1175
motor activity, 129
phencyclidine (PCP), 1175
phenylethylamine (PEA), 129
tolerance, 1175
Sequential presentation, 697
drinking
naloxone
palatability
satiation
Serotonergic neurons, 1
antidepressants
escape deficits
inescapable shock
learned helplessness
Serotonergic receptors, 805
antidepressants
model of depression
Serotonin, 1223
deprivation
eating
medial hypothalamus
norepinephrine (NE)
paraventricular nucleus (PVN)

Serotonin antagonists, 1207
dose-dependent effects
drug discrimination
5-methoxy-N,N-dimethyltryptamine (5-OMe DMT)
stimulus properties
Serotonin synthesis, 797
ethanol tolerance
limbic structures
vasopressin-like peptides
Sex differences
cocaine, 497
ethanol, 703
haloperidol, 497
radial arm maze performance, 703
self-administration, 497
tamoxifen, 497
Sexual behavior differentiation, 573
endogenous opioids
naltrexone
prenatal stress
Shock, 1163
adjunctive consumption
alcohol
drinking
extinction
lithium
stress
Shock avoidance, 439
CGS 8216
drug interactions
ethanol
naltrexone
timeout from avoidance
Shock escape learning, 693
apomorphine
dopaminergic mechanisms
Shock, uncontrollable, 415
p-chlorophenylalanine (PCPA)
stress
Shuttle avoidance, 567
amnesia
anisomycin
cycloheximide
drug interactions
naloxone
passive avoidance
Sidman avoidance schedule, 145
d-amphetamine
bin analysis
inter-response time
monkeys
Simple carbohydrate comparisons, 681
hypocaloric diets
insulin receptors
obesity
Simultaneous brightness discrimination, 939
d-amphetamine
two stage administration
Single-trial, 1101
conditioned place preference
drug reinforcement
morphine
Single unit activity, 607
ethanol effects
somatosensory cortex
Sleep time, 333
circadian rhythm
sedation hypnosis
strain differences
Smoking topography, 1245
carbon monoxide exposure
filter vent blocking
human studies
tobacco
Snails, 1201
analgesia
classical conditioning
environmental specific cues
habituation
morphine
stress
tolerance
Social isolation, 41
immobilization, acute
neurobiological responses
Social stress, 449
drinking
hamsters
high-calorie fluids
reproduction
Sodium pentobarbitol, 35
classical conditioning
cross tolerance
ethanol
Sodium valproate, 747
chlordiazepoxide
spatial behavior
Somatosensory cortex, 607
ethanol effects
single unit activity
Spatial behavior, 747
chlordiazepoxide
sodium valproate
Spatial memory, 521
BW813U
choline acetyltransferase (ChAT) inhibitor
radial maze performance
Spinal motoneurons, 89
cannabidiol
cats
electrophysiological properties
synaptic effects
Spontaneous chewing movements, 897
acute administration
antipsychotic drugs
chronic administration
tardive dyskinesia
Step through latencies, 979
exponential data analysis
passive avoidance
Stereoisomers, 375
fixed ratio/fixed interval schedule
locomotor activity
pentobarbital
secobarbital
variable interval schedule
Stereotypy
alpha$_2$-adrenergic antagonists, 155
amphetamine, 155
atropine, 985
clonidine, 985
drug interactions, 985
hotplate test, 933
in vivo, 155
locomotor activity, 155, 985
pemoline, 933
self-injurious behavior, 933
Stereotypy, apomorphine-induced, 1279
cyclo(leucyl-glycyl) (cLG)
dopamine receptors
haloperidol
supersensitivity
Steroidogenesis, 753
adrenal cortex
adrenocorticotrophin 1–24 (ACTH (1–24)
corticosterone synthesis
Stimulants, 277
investigatory behavior
locomotor activity
multivariate assessment
Stimulation-produced analgesia, 533
antinociceptive system
morphine
opiate tolerance
Stimulus control, 227
lysergic acid diethylamide (LSD)
pizotyline
verapamil
Stimulus properties
dose-dependent effects, 1207
drug discrimination, 785, 1207
metazocine, 785
5-methoxy-N,N-dimethyltryptamine (5-OMe DMT), 1207
monkeys, 785
self-administration, 785
serotonin antagonists, 1207
Strain differences
caffeine, 1271
circadian rhythm, 333
hypertension, 317
lesions, substantia nigra, 317
locomotor activity, 1271
open field, 317
sedation hypnosis, 333
sleep time, 333
striatal dopamine content, 317
theophylline, 1271
Stress
adjunctive consumption, 1163
alcohol, 1163
analgesia, 1201
buspirone, 457
p-chlorophenylalanine (PCPA), 415
classical conditioning, 1201
corticosterone secretion, 457
drinking, 1163
environmental specific cues, 1201
extinction, 1163
habituation, 1201
lithium, 1163
morphine, 1201
prolactin secretion, 457
shock, 1163
shock, uncontrollable, 415
snails, 1201
tolerance, 1201
Stress-induced analgesia, 181
classical conditioning
tail flick
Striatal dopamine content, 317
hypertension
lesions, substantia nigra
open field
strain differences
Striatal dopamine system, 865
DOPAC/DA ratio
dopamine release
unilateral barpressing
Striatum, 1095
dopamine metabolism

feeding behavior
ingestion
nucleus accumbens
Subdiencephalic rat brain, 347
prostaglandin
pyrexia
Subjective ratings, 659
human studies
marijuana smoking
tobacco smoking
Substance P, 469
avoidance learning
inhibitory avoidance
Sucrose, 1001
drinking
morphine
naloxone-precipitated withdrawal
physical dependence
Sucrose concentration, 219
anhedonia
licking
pimozide
Supersensitivity, 1279
cyclo(leucyl-glycyl) (cLG)
dopamine receptors
haloperidol
stereotypy, apomorphine-induced
Sympathomimetics, 233
locomotor behavior
opiates
psychostimulants
Synaptic effects, 89
cannabidiol
cats
electrophysiological properties
spinal motoneurons

Tail flick, 181
classical conditioning
stress-induced analgesia
Tamoxifen, 497
cocaine
haloperidol
self-administration
sex differences
Tardive dyskinesia
acute administration, 897
antipsychotic drugs, 897
cholinesterase inhibitors, 1217
chronic administration, 897
perioral behaviors, 1217
physostigmine, 1217
spontaneous chewing movements, 897
Temporal analysis, 995
conditioned taste aversion
duration of action
tryptamine
Testosterone, 823
chicks
memory
Δ⁹-Tetrahydrocannabinol (Δ⁹-THC), 827
in vitro
metabolic interactions
phencyclidine (PCP)
Ca^{++}-precipitated liver microsomes
Tetralin analogues, 135
drug discrimination
8-hydroxy-2-(di-n-propylamino) tetralin (8-OH DPAT)
ketanserin pretreatment
Tetrodotoxin, 857
lordosis disruption
midbrain infusions
procaine
Theobromine, 769
adenosine receptors
hypothermia
inbred strains
locomotor activity
methylxanthines
Theophylline, 1271
caffeine
locomotor activity
strain differences
Thermic response shifts, 83
conditioned hyperactivity hypothesis
drug interactions
Thermoregulation
Ca^{++}-ATPase activity, 549
calcium channel antagonists, 555
cholinesterase inhibition, 1071
clinical chemistry, 1071
dihydropyridine receptors, 549
drug interactions, 555
heat, 1071
hyperthermia, 555
pyridostigmine, 1071
5-Thioglucose, 59
2-deoxyglucose
feeding behavior
hyperphagia
lateral hypothalamus
ventromedial hypothalamus
Time-dependent modulation, 919
amphetamine-induced hyperactivity
estrogen
Time estimation, 1185
D_2 receptors
dopamine
internal clock speed
neuroleptics
Timeout from avoidance, 439
CGS 8216
drug interactions
ethanol
naltrexone
shock avoidance
Tizanidine, 835
antinociception
drug comparisons
drug interactions
morphine
tolerance
Tobacco, 1245
carbon monoxide exposure
filter vent blocking
human studies
smoking topography
Tobacco deprivation, 879
electroencephalographic effects
human studies, smokers
nicotine gum
Tobacco smoking, 659
human studies
marijuana smoking
subjective ratings
Tolerance
acoustic startle, 1175
acute administration, 1195
age differences, 359
aggression, 1195
ambient temperature, 667
amphetamine, 1175
analgesia, 1201
antinociception, 835
benzodiazepines, 1237
body temperature, 1293
l-cathinone, 13
cats, 359
chickens, 1237
chlordiazepoxide, 1237
chronic administration, 13, 667, 1195
chronic infusion, 483
classical conditioning, 1201
cocaine, 1175
cross-tolerance, 1175
diisopropylfluorophosphate (DFP), 1293
drug administration, 13
drug comparisons, 835
drug interactions, 835
environmental specific cues, 1201
ethanol, 667
habituation, 1175, 1201
heart rate, 1293
hypothermia, ethanol-induced, 667
intrathecal injection, 483
locomotor activity, 1293
magnesium, 1195
morphine, 835, 1201
muscarinic receptors, 1293
phencyclidine (PCP), 1175
phencyclidine (PCP) metabolites, 359
^{3}H-quinuclidinyl benzilate (^{3}H-QNB) binding, 1293
respiration rate, 1293
sensitization, 1175
snails, 1201
stress, 1201
tizanidine, 835
tonic immobility, 1237
Tonic immobility
benzodiazepines, 1237
chickens, 1237
chlordiazepoxide, 1237
hippocampal 5-HT activity, 781
rabbits, 781
tolerance, 1237
Tripelennamine, 629
brain stimulation
drug interactions
nalbuphine
reward threshold
Tryptamine, 995
conditioned taste aversion
duration of action
temporal analysis
L-Tryptophan, 849
amphetamine self-administration
Two-bottle choice paradigm, 431
benzodiazepines
conditioned taste aversion
drinking
polydipsia
Two stage administration, 939
d-amphetamine
simultaneous brightness discrimination
Type 2 receptors, 1145
benzodiazepines
convulsions
hyperactivity
neonates
Tyrosine hydroxylase activity, 763
adrenergic receptors

dopamine receptors
marijuana
perinatal exposure
L-Tyrosine, 1027
amphetamine self-administration
brain catecholamines

Ulcer proliferation, 1083
restraint stress
voluntary ethanol consumption
Unilateral barpressing, 865
DOPAC/DA ratio
dopamine release
striatal dopamine system
Unrestrained animals, 487
intracerebral cannula
rodents, small

Valproic acid, 929
delayed-matching-to-sample
drug interactions
phenobarbital
phenytoin
pigeons
Variable interval schedule
drug interactions, 149
fixed ratio/fixed interval schedule, 375
imipramine, 149
locomotor activity, 375
methadone, 149
pentobarbital, 375
pigeons, 149
secobarbital, 375
stereoisomers, 375
Vasopressin
barrel rotation, 583
consolidation, 1125
lesions, kainic acid, 583
memory effects, time related, 1125
nicotine, 583
passive avoidance behavior, 1125
prostration, 583
retrieval, 1125
vasopressin analogues, 1125
vestibular cerebellum, 583
Vasopressin analogues, 1125
consolidation
memory effects, time related
passive avoidance behavior
retrieval
vasopressin
Vasopressin-like peptides, 797
ethanol tolerance
limbic structures
serotonin synthesis
Ventral tegmental area, 959
circling, opiate-induced
dopaminergic system
opiate receptors
Ventromedial hypothalamus, 59
2-deoxy-D-glucose
feeding behavior
hyperphagia
lateral hypothalamus
Verapamil, 227
lysergic acid diethylamide (LSD)
pizatyline
stimulus control
Vestibular cerebellum, 583
barrel rotation
lesions, kainic acid
nicotine
prostration
vasopressin
Voltammetric recording, 325
in vivo
nafion-coated electrodes
Voluntary ethanol consumption, 1083
restraint stress
ulcer proliferation

Water, 1159
adjunctive consumption
alcohol
drinking
extinction
lithium
Water balance, 77
drinking
opioid agonists
Water deprivation, 1153
2-deoxy-D-glucose
glucoprivation
hypophagia
liquid diet
Water maze, 141
brain iron-deficiency
learning
Water reinforcement, 1231
anhedonia
haloperidol
partial reinforcement extinction effect
reward omission, periodic
Withdrawal, precipitated, 1263
morphine
reinforcement threshold
response rate
self-stimulation
withdrawal, spontaneous
Withdrawal, spontaneous, 1263
morphine
reinforcement threshold
response rate
self-stimulation
withdrawal, precipitated
Working memory, 633
delayed response
discrimination
response bias
scopolamine

AUTHOR INDEX

Abed, W. T., 949
Abiru, T., 463
Abla, K. A., 1271
Abood, L. G., 583, 589
Addington, S., 989
Akiyoshi, J., 805
Allweis, C., 979
Alpern, H. P., 333, 1077
Alvarado, M. C., 487
Amalric, M., 233
Anderson, D., 415
Andersson, U., 897
Andrew, R. J., 823
Anisman, H., 29
Apfelbaum, M., 681, 913
Armstrong, D. E., 561
Aronstam, R. S., 985
Avery, D. D., 7
Ayhan, I. H., 215
Azar, A. P., 381

Baigts, F., 681
Balster, R. L., 785
Bapna, J. S., 59
Bardo, M. T., 1101
Barnett, G., 365
Barrett, J., 1089
Barrett, J. E., 371
Bartles, R. R., 1153
Bassett, J. R., 753
Bayn, P., 681
Beaman, C. M., 697
Beaton, J. M., 1191
Beckstead, J. W., 1237
Benedikt, R. A., 889
Benedito, M. A. C., 223
Bengelloun, W. A., 903
Bennett, E. L., 487
Benowitz, N. L., 1181
Ben-Shahar, O., 939
Berge, O.-G., 883
Bergman, J., 973
Bethea, C. L., 457
Betoulle, D., 913
Birbeck, K.-A., 747
Blackburn, J. R., 1095
Blundell, J. E., 123
Bodnar, R. J., 171
Bolger, G. T., 45, 51
Bolin, J., 1107
Bondesson, U., 897
Bowen, D. J., 1131
Bowman, R. E., 1117
Brady, J. V., 577
Bray, G. A., 733
Braz, S., 223
Breese, G. R., 63
Bridges, R. S., 1007
Brne, T., 1107
Brown, R., 107
Browne, R. G., 1051
Busccafusco, J. J., 985
Buchanan, G. D., 527
Buchanan, S. L, 423
Burks, T. F., 77
Burton, C. K., 599
Burton, M. J., 23, 711
Bushnell, P. J., 161

Callahan, M. F., 641
Cam, G. R., 753
Camarena, M. L., 1217
Camp, C. H., 813, 1231
Cannon, D. J., 117
Cao, W., 769, 1271
Carney, J. M., 769, 1271
Carnoy, P., 503
Carr, G. D., 17
Carr, L. A., 763
Carson, J., 521
Castellano, C., 181
Chamberlain, J., 95
Chandra, D., 59
Chapin, J. K., 607
Chernichovsky, D., 979
Cho, C. H., 775
Church, W. H., 865
Chute, S., 129
Clark, W. G., 481
Cleary, J., 149
Coenen, A. M. L., 329
Coffey, P. J., 711
Collins, A. C., 1293
Cooper, S. J., 99, 341
Cordoba, F., 71
Coscina, D. V., 401

Couch, L., 117
Crabbe, J. C., 289
Crawley, J. N., 45
Cunnane, S. C., 1285

Dai, S., 1001
Dalton, J. C. H., 497
DaVanzo, J. P., 95
Dawson, R. G., 1089
de Belleroche, J. S., 943
Deckel, A. W., 297
DE Jong, W., 317
DeLeon-Jones, F. A., 1279
Deupree, D., 77
De Wied, D., 1125
D'Onofrio, G., 651
Duka, T., 595
Durel, L. A., 371
Durivage, M. E., 155

Edwards, E., 415
Eldred, N. L., 449
El Mestikawy, S., 1
Enginar, N., 953
Ettenberg, A., 791, 813, 1231
Eury, S. E., 1131
Evans, K. R., 1149
Exley, R. J., 989

Falcou, R., 913
Farabollini, F., 781
Fasmer, O. B., 883
Feldon, J., 939
Fibiger, H. C., 1095
Fields, J. Z., 1279
Filart, R., 381
File, S. E., 1145
Fishbein, W., 1253
Fishman, M. W., 577
Fletcher, P. J., 23, 995
Foltin, R. W., 577
Fowler, S. C., 219, 615, 791
Francesconi, R., 1071
Franklin, S. R., 925
Fudala, P. J., 1041
Fumeron, F., 681
Funahashi, M., 1035
Furukawa, T., 463

Gaffori, O. J. W., 1125
Galizio, M., 439
Gallup, G. G., Jr., 1237
Garcia-Valdez, K., 1195
Gardiner, I. M., 943
Geis, L. S., 1027
Geyer, M. A., 277
Gianutsos, G., 129
Gibbs, M. E., 823
Giesecke, Jr., A. H., 481
Giuditta, A., 651
Glavin, G. B., 1083
Glennon, R. A., 135, 1207
Glick, S. D., 1021
Glick, Z., 491
Glowa, J. R., 973
Goeders, N. E., 191
Gonzalez, L. P., 1279
Gori, G. B., 1181
Gorzalka, B. B., 111
Gramling, S. E., 219, 615
Grassi, S., 583, 589
Grecksch, G., 1137
Griffiths, R. R., 659
Grondin, L., 903
Grunberg, N. E., 1131
Güngör, M., 953
Gunne, L. M., 897

Hahn, B., 29
Hall, A., 1083
Hamilton, M. H., 943
Hamon, M., 1
Hara, C., 757
Hardwick, W. C., 117
Harlan, R. E., 857
Hashimoto, H., 411
Hatipoğlu, I., 953
Hawkins, C., 1153
Heise, G. A., 633
Hempel, A. G., 989
Henault, M. A., 297
Henn, F. A., 415
Henningfield, J. F., 659, 879
Hepler, D. J., 293
Herberg, L. J., 943
Herning, R. I, 879
Hitunen, A. J., 393
Hines, G., 1159, 1163
Hirst, M., 543, 1201
Hizal, A., 953
Ho, I. K., 599
Hole, K., 883
Hollingsworth, E., 933
Hook, R., 843
Horrobin, D. F., 1285
Hoskins, B., 599
Howard-Butcher, S., 359
Hruby, V., 77
Hsiao, S., 77
Huang, Y.-S., 1285
Hubbard, R., 1071
Hughey, D., 521
Hunter, G. A., 697
Husain, S., 827
Huston, J. P., 469
Hydén, H., 651

Ingram, D. K., 673
Iwamoto, E. T., 1041
Izenwasser, S. E., 1195

Jacobson, W., 527
Jähkel, M., 41
Jakubovic, A., 1095
Järbe, T. U. C., 393
Jarvis, M. J., 727
Jhanwar-Uniyal, M., 381
Johansson, P., 897
Johnson, J., 415
Jones, B., 889
Jork, R., 1137
Justice, A., 263
Justice, J. B., Jr., 865

Kalant, H., 667, 797
Kamatchi, G. L., 59
Kameyama, T., 567, 835
Kamimura, H., 411
Kamiya, H., 463
Kantak, K. M., 1195
Kaplan, E., 843
Karas, C. A., 929
Karler, R., 89
Kastin, A. J., 757, 1303
Katz, N. L., 1107
Kavaliers, M., 543, 1201
Kempf, E., 1211
Khanna, J. M., 667
Kimura, H., 1035
Kinsley, C. H., 1007
Kirkham, T. C., 123, 341
Klimek, V., 329
Knudson, K., 1223
Kohda, H., 1035
Kokkinidis, L., 1175
Koo, M. W. L., 775
Koob, G. F., 233
Kornetsky, C., 629
Koyuncuoğlu, H., 953
Kozawa, T., 567
Kozlowski, M. R., 1051
Kramer, E., 171
Krantz, D. S., 371
Ktorza, A., 681
Kulkosky, P. J., 1067

LaCerra, M. M., 791
Ladowsky, R. L., 269
Lakhdar-Ghazal, N., 903
Lamé, M. W., 827
Lander, N., 393
Lasoń, W., 967
Le, A. D., 667
Leccese, A. P., 849
Lee, J. M., 1279
Leibowitz, S. F., 381, 1223
Lerer, B. E., 293
Leung, C. M. K., 1001
Leva, N., 1071
Levin, E. D., 1117
Levine, M. S., 359
Li, T.-K., 1013
Liao, R.-M., 615
Licko, V., 365
Lieber, P., 1279
Lipton, J. M., 481
Liu, W.-F., 1191
Livesey, D. J., 1089
Livesey, P. J., 1089
Livosky, M., 7
Lodi, L., 781
Logan, L., 769
LoLordo, V. M., 561
Lorens, S. A., 457
Lukas, S. E., 889
Lumeng, L., 1013
Lupien, J. R., 733
Lupo, C., 781
Luttinger, D., 155
Lynch, C. J., 1181
Lyness, W. H., 849, 1027

McCallister, L. W., 481
McConnaughey, M. M., 95
McCown, T. J., 63
McEvoy, P. M., 35
McIntyre, T. D., 333, 1077
McKinney, J., 1153
McMillan, D. E., 117, 209

Maier, D. M., 703
Maiti, A., 583, 589
Majeed, N. H., 967
Malin, D. H., 989
Martin, P., 1
Martin, W. R., 843
Masten, V. L., 277
Mastropaolo, J., 201
Masur, J., 739
Matsuno, K., 835
Matthew, C., 1071
Matthies, H., 1137
Mattingly, B. A., 693
May, E. L., 785
Mechoulam, R., 393
Meck, W. H., 1185
Mehta, A. K., 1059
Mendelson, J. H., 889
Mendelson, S. D., 111
Menna, T., 651
Meyerson, L. R., 1279
Michael, R. P., 919, 1263
Mintz, M., 1307
Moerschbaecher, J. M., 201
Mogilnicka, E., 329, 743
Mokler, D. J., 717
Molloy, A. G., 249, 985
Monaghan, E. P., 573
Montogomery, A. M. J., 23, 711
Marato, G. S., 739
Mori, T., 411
Morozova, A. S., 533
Mosberg, H. I., 77
Moss, D. E., 1217
Mostofsky, D. I., 141
Mueller, D., 325, 933
Muir, J. L., 107
Mũnoz-Blanco, J., 71

Nabeshima, T., 567, 835
Nader, M., 149
Nagayama, H., 805
Nakajima, T., 411
Nakao, J., 411
Napier, T. C., 63
Nassif-Caudarella, S., 1211
Neill, D. B., 865
Neisewander, J. L., 1101
Nemeth-Coslett, R., 659
Ng, K. T., 823
Nichols, N. F., 255
Nobrega, J. N., 401
Noto, T., 411
Numan, R., 1111

O'Boyle, K. M., 249
Oehler, J., 41
Ogle, C. W., 775, 1001
O'Keefe, M. K., 659
Oliverio, A., 181
Olorundare, O. E., 347, 353
Olton, D., 521
Ono, N., 463
Oshiro, A., 491
Ossenkopp, K.-P., 269

Palaoğlu, Ö., 215
Papadakos, P., 1223
Papasava, C., 623
Papasava, M., 623
Parker, K. M., 1271
Patterson, T. A., 487
Paul, S. M., 45
Pavone, F., 181
Pease, V., 1071
Perone, M., 439
Perrone Capano, C., 651
Peters, D. A. V., 873

Pettit, H., 933
Pfaff, D. W., 857
Pfister, H. P., 107
Phillips, A. G., 1095
Picker, M., 929
Pickworth, W. B., 879
Pillai, N. P., 549, 555
Pires, M. L. N., 739
Pisa, M., 689
Pohorecky, L. A., 703
Poling, A., 929
Popplewell, D. A., 711
Porreca, F., 77
Poshivalov, V. P., 515
Post, C., 883
Powell, D. A., 423
Przewłocka, B., 329, 967
Przewłocki, R., 967
Pugh, M. T., 249

Rabillon, B., 681
Rafferty, M. F., 45, 51
Rager, D. R., 1237
Raigoza, V. P., 1067
Randich, A., 641
Ravard, S., 503
Reader, T. A., 903
Rech, R. H., 717
Reichert,-Hunter, G. L., 697
Reid, L. D., 697
Rennert, O. M., 769, 1271
Reyes, E., 1217
Rhea, K., 1153
Rhodes, D. H., 1153
Rice, K. C., 51
Rigby, P., 673
Riley, E. P., 1021
Ritzmann, R. F., 1279
Rizkalla, S. W., 681
Roache, J. D., 431
Roberts, D. C. S., 497
Robinson, R. G., 263
Rockman, G. E., 1083
Rodriguez, L. A., 1217
Rosecrans, J. A., 1207
Rosenweig, M. R., 487
Ross, D. H., 549, 555
Rothfeld, J. M., 857
Rudy, T. A., 347, 353
Rush, D. K., 145
Russo, P. V., 277

Sabol, K. E., 865
Saito, R., 463
Sakai, D. H., 487
Sanberg, P. R., 231, 297
Sanchez, M. R., 1067
Sanger, D. J., 537
Schaefer, G. J., 1263
Schechter, M. D., 13, 337
Schlemmer, R. F., Jr., 1107
Schmidt, J., 41
Schnur, P., 1067
Schreur, P. J. K. D., 255
Scoles, M. T., 1169
Seale, T. W., 769, 1271
Sethy, V. H., 925
Seyrig, J. A., 913
Shahid Salles, K., 583, 589
Sherman, L. C., 717
Shikata, I., 1035
Shiromani, P. J., 1253
Shivers, B. D., 857
Shor-Posner, G., 381
Shulz, D., 979
Siegel, S., 1169
Simon, P., 1, 503
Singer, G., 623
Skolnick, P., 45, 51
Slifer, B. L., 785
Sloan, J. W., 843
Smith, D. G., 849, 1027
Smith, F. L., 849, 1027
Smith, J. E., 191
Smolen, A., 1293
Smolen, T. N., 1293
Sod-Moriah, U., 491
Sorensen, S. M., 607
Soubrie, Ph., 1, 503
Souza, M. L. O., 739
Spangler, E. L., 673
Speisky, M. B., 797
Spencer, B. A., 439
Spencer, R. L., 77
Sperber, E. S., 171
Spickett, T. J., 1089
Spielmann, D., 681
Spoerlein, M. T., 959
Ståhle, L., 473
Steece, K. A., 1279
Stephens, D. N., 595
Stevens, C. W., 483
Stitzer, M. L., 1245
Stoudt, K. W., 717
Sugimoto, A., 835
Sunal, R., 511
Sutherland, C., 269
Sweeney, J., 521
Swerdlow, N. R., 233
Szechtman, H., 689
Szewczak, M. R., 959

Talanian, R. V., 697
Tang, A. H., 925
Taukulis, H. K., 83
Thiebot, M. H., 1
Thompson, D. M., 185, 201
Thompson, T., 149, 365
Ticku, M. K., 1059
Tobo, M., 805
Tomaz, C., 469
Tomer, R., 1307
Toniatti, C., 651
Treit, D., 561
Troncone, L. R. P., 223
Tufik, S., 223
Turano, P., 415
Turkanis, S. A., 89

Ungerstedt, U., 473
Unterwald, E. M., 629
Urban, J. H., 457

Vaccarino, F. J., 233, 1149
Valdman, A. V., 515
Van de Kar, L. D., 457
van den Buuse, M., 317
van Luijtelaar, E. L. J. M., 329
Veeraragavan, K., 59
Veldhuis, H. D., 317
Velley, L., 1211
Versteeg, D. H. G., 317
Vickers, G. J., 497
Vinick, F. J., 1051
Viscardi, A. P., 633

Waddington, J. L., 249
Walters, D. E., 763
Ward, I. L., 573
Ward, O. B., 573
Wash, C., 843
Watson, P. J., 1153
Weiner, I., 939
Weiss, G. F., 1223
Weissman, B. A., 51
Wemerman, B., 503
Wenger, G. R., 375
Wenger, J. R., 35
Wenk, G., 521
Wessinger, W. D., 209
West, C. H. K., 919
West, R. J., 727
White, N. M., 17
Wilkinson, M., 527
Wilks, L. J., 1145
Willner, P., 747
Winsauer, P. J., 185, 201
Winter, J. C., 227
Wise, D. A., 449
Woods, S. C., 35
Woodward, D. J., 607

Yaksh, T. L., 483
Yamada, S., 835
Yehuda, S., 141
Yerbury, R. E., 99
Yingling, J. E., 1245
Youdim, M. E. H., 141
Young, J., 1071
Young, R., 1207
Younglai, E. V., 527
Yu, D. S. L., 849, 1027
Yusta, B., 71

Zabik, J. E., 431
Zacharko, R. M., 29
Zacny, J. P., 1245
Zadina, J. E., 1303
Zimmerberg, B., 1021
Zvartau, E. E., 533